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Background: Irritable bowel syndrome (IBS) is the most common functional gastrointestinal 
disorder, defined by recurrent abdominal pain or discomfort, associated with defecation 
and/or altered bowel habits. Due to the lack of structural etiology, and curative therapy, these 
patients have been treated symptomatically. The treatment is recommended to be 
individualized, where the options are a combination of guidance on diet and lifestyle, 
pharmacological therapy and psychological interventions. The worldwide prevalence is high 
and it contributes to reduced quality of life and major healthcare costs. There is a need for 
treatment that can shorten the waiting line for patient education, reduce healthcare costs and 
help more people independently of geographic location, therefore an eHealth program was 
developed and implemented.  
Aim: The primary aim of the prospective, open pilot study, was to evaluate whether the 
eHealth program could be effective as a healthcare measure. This was assessed, based on the 
effect of the program itself, but also in comparison with the effect of the current program; the 
physical IBS-school at LMS. 
Design and methods: 52 patients who had got the IBS-diagnosis from either their general 
practitioner (D93) or by a specialist in gastroenterology (k58), were included in the 6 months 
long study. They participated in the web-based, interdisciplinary, self-management program. 
The program was based on 5 different modules with professional content, each compiled by 
gastroenterologist, physiotherapist, psychiatrist and clinical dietitian. It was implemented in 
Checkware’s technical platform by Helse Bergen- Section for eHealth. To assess the effect of 
the program, the participants were asked to complete the six questionnaires; Rome III criteria, 
IBS-QOL, IBS-SSS, HADS, RAND-36 and NKFM at three time points; at baseline, and after 
3- and 6 months, in addition to CSQ-8, at 3 months after the start-up. Control group 1 and 2 
consisted of IBS-patients, which participated in the regular, physical, IBS-school at LMS and 
an extended, physical, IBS-school at LMS, respectively.  
Results: Of the 52 study participants included in the eHealth program, 40 completed the 3 
months evaluation and 31 completed the 6 months evaluation. The analysis of eHealth 
program (I) followed the participants who completed the 6 months evaluation. 4 out of 5 IBS 
symptoms significantly improved from baseline to after 3 months, with a mean overall 





scores increased significantly between the latter two time points, with a mean overall 
improvement of 9.2 (95% CI: 4.2, 14.1, p= 0.001). In control group 1, mean overall IBS 
symptoms and mean IBS-QOL overall, numerically improved from baseline to after 3 
months, with 7.0 (95% CI: -21.8, 35.8, p= 0.617) and 3.9 (95% CI: -7.5, 15.3, p= 0.485), 
respectively. In the eHealth program (I), 3 out of 5 IBS symptoms significantly improved 
from baseline to after 6 months, with a mean overall reduction of 78.7 (95% CI: 37.4, 120.0, 
p= 0.001). 7 out of 8 IBS-QOL subscale scores improved significantly between the latter time 
points, with a mean overall improvement of 10.1 (95% CI: 5.9, 14.3, p= 0.00003). In control 
group 2, the overall IBS symptom scores numerically decreased from baseline to after 6 
months, with a mean of 32.3 (95% CI: -5.6, 70.2, p= 0.094). 
Conclusion: In this prospective, open pilot study, we found statistically significant 
improvement in IBS symptoms and health-related quality of life, according to IBS-QOL. 
There was also a greater mean improvement in symptoms- and IBS-QOL scores when 
compared with the control groups, but neither of the scores in the control groups were 
statistically significant changed. However, it indicates that the eHealth program is not less 
effective than the IBS-school at LMS. Altogether, it leads us to the conclusion that the 
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1.1 Functional gastrointestinal disorders (FGIDs) 
Many patients suffer from functional gastrointestinal disorders (FGIDs), but there are also 
many people in the general population who are bothered by symptoms related to these 
disorders (1). These patients have often been described as having “functional 
symptoms/problems”, and has due to the lack of structural etiology, been treated 
symptomatically (2, 3). In 2006, the Rome foundation published Rome III, that define the 
diagnostic criteria as well as a classification system for FGIDs (1). The classification system 
divides FGIDs into 6 domains for adults; “esophageal (category A); gastroduodenal (category 
B); bowel (category C); functional abdominal pain syndrome (category D); biliary (category 
E); and anorectal (category F)”, in addition to 2 domains for pediatrics GI which is divided by 
age: “neonate/toddler (category G); and child/adolescent (category H)” (1). Each domain 
consists of different subcategories, i.e.: functional bowel disorders (category C) consists of, 
among others, the subcategory irritable bowel syndrome (category C1) (1). 
 
1.2 Irritable bowel syndrome  
Of all functional gastrointestinal disorders, IBS is the most common, which is defined by 
recurrent abdominal pain or discomfort, which is associated with defecation and/or altered 
bowel habits (4-6). Even though IBS is not a life-threatening disorder, it still contributes to 
significantly reduced quality of life, and major healthcare costs both directly and indirectly, 
by patient care and absenteeism at work (4, 5, 7, 8). It's been reported that IBS patients' 
quality of life, has long been underestimated, and that these patients have a lower HRQOL 
than patients with other diseases, like diabetes, gastroesophageal reflux disease, and end-stage 
renal disease (9). 
 
1.2.1 Epidemiology 
In general, the prevalence and incidence rates of IBS differs from one country to another, 
depending on the study population, which criteria the study has used to define IBS and what 
type of study methodology has been utilized (4, 10, 11). A meta-analysis which performed a 
systematic review to assess the global prevalence of IBS in adults (15 years or older), 





They identified a worldwide IBS prevalence of 11.2% (95% CI, 9.8% -12.8%), with 
variations between countries and criteria used. For example, the prevalence in studies using 
Manning criteria was 14% (95% CI, 10.0% -17.0%), while Rome I criteria was 8.8% (95% 
CI, 6.8% -11.2%) and Rome II criteria were 9.4% (95% CI, 7.8% -11.1%) (11). The latter 
meta-analysis and other studies have found a higher prevalence in women than in men (4, 7, 
10, 11), and there is a higher proportion of people suffering from IBS in individuals younger 
than 50, compared to those older than 50 (10, 11). Unfortunately, there is not sufficient 
enough data, able to determine how socioeconomic status affects the prevalence of IBS (10, 
11).   
 
1.2.2 Etiology and Pathophysiology 
Despite the large proportion of patients suffering from IBS, the pathophysiology is still not 
fully understood (12, 13). Irritable bowel syndrome is a heterogeneous disorder, and it has 
been suggested to be a generic term for many diseases with different pathogenesis, but with 
the same symptoms (4, 8, 13). This means that IBS is a multifactorial syndrome, where no 
single abnormality is consistent for all patients with IBS symptoms (13, 14). Figure 1 shows 
different factors that may play a role in the pathogenesis of IBS. It has been suggested that 
genetic predisposition, various environmental factors and psychosocial factors can contribute 
to an increased vulnerability of developing IBS (8, 10). Events like enteric infection, may play 
a role as precipitating factors (may cause so-called “post-infectious IBS) (10, 15). All of these 
factors may contribute to different pathophysiological mechanisms like increased intestinal 
permeability, altered gut immune activation and changed microbiota (8, 10, 13). Furthermore, 
these various factors may contribute to a dysregulation of the brain-gut axis, which 



















Figure 1: Overview of different factors that possibly can play a role in the pathophysiology of IBS, 
made based on figure from Heidelbaugh et al and Schoenfeld (10, 13) and with some modifications 
from Ford et al (8). 
 
1.2.3 Signs and symptoms 
Typical symptoms found in IBS patients are abdominal pain and cramping, 
bloating/distention, constipation, loose/frequent stools and flatulence, some also experience 
defecation straining, urgency and sensation of an incomplete bowel movement (4, 6, 16). IBS 
patients can also experience that symptoms change over time, i.e.: pain location and altered 
stool patterns may alter from time to time (4, 16).  
Patients with IBS often experience multiple comorbidities that contribute to their disease 
burden (4, 14, 17-19). These can be divided into gastrointestinal disorders (functional 
gastroesophageal reflux and functional dyspepsia), psychiatric disorders (depression, anxiety, 
and somatization), and finally the nongastrointestinal nonpsychiatric disorders (fibromyalgia, 
chronic fatigue syndrome, temporomandibular joint disorder, chronic pelvic pain, migraine 
headaches, interstitial cystitis and dyspareunia) (4, 14, 17-19). It has also been indicated that a 




Because of the absence of pathology that can explain the IBS symptoms, it has been difficult 
to develop a non-invasive diagnostic test with high accuracy (8). Efforts have been made to 





better than symptom-based criteria (8, 21). The identification of IBS is therefore a symptom-
based approach where the diagnosis is based on the Rome III diagnostic criteria (Figure 1) 
and the exclusion of organic disease (1, 3, 4, 6, 7). The Rome III criteria implies “recurrent 
abdominal pain associated with defecation and/or a change in stool, at least 3 days per month 
in the last 3 months, and with symptom onset at least 6 months before the diagnosis” (4, 6).  
 
IBS should be diagnosed based on clinical history, physical examination and laboratory tests 
(4, 14). To exclude organic disease, patients who fulfill the Roma III criteria for IBS are also 
investigated for red flag symptoms like unintentional weight loss, fever, age of symptom 
onset after 50 years, rectal bleeding, anemia and family history of organic gastroenterological 
disease (4, 14). Only if clinically indicated, as a positive discovery of the latter, the patient 
should be further investigated (like a colonoscopy) to check for any anatomic and 
physiological abnormalities, which is what distinguishes functional bowel disorders from 
other GI disorders (4, 14). 
 
IBS is subcategorized into 3 different subtypes based on their predominantly stool 
consistency; i) IBS with predominant constipation (IBS-C), ii) IBS with predominant diarrhea 
(IBS-D) and iii) IBS with irregular bowel habits (IBS-M), where the patients experience a 
mixture of constipation and diarrhea (4, 6, 14). Patients who fulfill the Rome III criteria for 
IBS, but do not have bowel habits that allow them to be accurately categorized into one of 
these three subtypes mentioned, are unsubtyped as having IBS-unclassified (IBS-U) (6, 14). 
The Bristol Stool Form Scale (BSFS) (Figure 2) is often recommended to be used as a record 
for stool consistency (14, 22, 23). Figure 3 presents how Bristol Stool Form Scale potentially 
can subtype IBS. Here, IBS is subcategorized according to the predominant stool consistency 
that is present more than 25% of the time (14, 23). In IBS-C, stool from type 1 and 2 on the 
Bristol Stool Form Scale (Figure 2), are present more than 25% of the time (14, 23), while 
type 6 and 7 are present less than one quarter of the time. The opposite applies for IBS-D. In 
IBS-M, both loose and hard stools are frequently present (14, 23), whereas with IBS-U there 
is no stool consistency that dominates (14, 23). It is important to note that IBS patients 
occasionally have normal bowel habits. Therefore, in clinical practice, one will categorize the 





usually dominates when the patient experiences abnormal stool (14, 23). If a patient meets the 
Rome III criteria, they are not only subtyped based on their predominant stool pattern, but 
they are also categorized by the severity of their symptoms (23). The patients are categorized 
into mild-, moderate- and severe IBS, or remission, depending on their symptom score (see 













Figure 2: Rome III Diagnostic criteria for irritable bowel syndrome and “red flags” adapted from figures 









Figure 3: The Bristol Stool Form Scale. Lacy et al. Bowel Disorders, Gastroenterology, 2016; 150(6). 















Figure 4: Rome IV IBS subtypes: stool form. Lacy et al. Bowel Disorders, Gastroenterology, 2016; 
150(6). P 1393-1407. Figure 2 (B) (14). 
 
1.2.5 Treatment 
Currently, there is nothing that cures IBS, and since the patient group is highly heterogeneous, 
the treatment is recommended to be individualized based on the patient’s predominant 
symptoms (symptom type and severity) (8, 14, 17, 25). The treatment options for IBS are a 
combination of guidance on diet, general lifestyle and physical activity, as well as 
pharmacological therapy and psychological interventions (4, 15, 26). Figure 5 shows 
examples of different treatment options for IBS. Although this thesis does not address all the 
individual treatment options, studies have evaluated both the effect and quality of evidence, as 
well as cost, of the various therapy alternatives (8, 27). The latter figure shows, among other 
things, medications that are recommended to treat specific symptoms of IBS, such as diarrhea, 
constipation, abdominal pain and bloating (15, 26).  
 
1.2.5.1 Non-pharmacological treatment 
Because of the incomplete utility of pharmacological treatment for IBS (28), different studies 
have looked at the effect of different psychological treatments for irritable bowel syndrome 





greater effectiveness, than controls in waiting line (30). This was assessed based on decreased 
IBS-like symptoms and improved psychological state and quality of life (QOL) (30). But it 
was only reduction of IBS-like symptoms, which was more effective in CBT, compared with 
controls who received routine standard care and medical therapy. The study also indicated 
that the effect of IBS could possibly be maintained by long-term follow-up (30). Another 
meta-analysis has shown that Mindfulness-based therapy (MBT) can also be effective in the 
treatment of IBS (31). 
 
It has also been recommended to give IBS patients guidance for self-help to cope with IBS 
(15, 26). This contains among other things, of recommendations of inspiring patients with low 
physical activity to increase their level of activity, which is supported by studies, that have 
shown that exercise possibly can improve GI symptoms (32, 33). Dietary guidance is also one 
of the first-line treatments, as many IBS patients claim that specific parts of the diet can be a 
trigger for their symptoms (8, 15, 26). Bohn et al report that this is associated with a high 
degree of symptoms and reduced quality of life (34). The traditional IBS diet is compiled on 
the basis of the guidelines from the National institute for Health and Care Excellence (NICE) 
and the British Dietary Association (BDA) (35). The latter’s guidelines focus among other 
things, on restrictive intake of alcohol, spicy and fatty food (36). Examples of 
general/standard advices given, based on the NICE guidelines are; “have regular meals and 
take time to eat”, “reduce intake of alcohol and fizzy drinks”, “limit fresh fruit to 3 portions 
per day”, “people with diarrhea should avoid sorbitol (…)” and so on (26).  
 
The effect of probiotics as an alternative treatment for IBS is controversial, and a systematic 
review and meta-analysis found that probiotics can enhance the overall symptoms modestly 
(37). They concluded that probiotics could possibly alleviate IBS-like symptoms, but in future 
studies it is also necessary to determine which type of probiotics is best effective and what is 
the optimal dose for which subgroup of patients (37). The lack of fiber as a possible cause of 
IBS-like symptoms, is a wide perception, and studies have shown that soluble fiber can be 
effective in the management of IBS, especially psyllium (25, 38-40). There has also been high 
interest around the effects of the low FODMAP diet, as a treatment option for irritable bowel 





Treatment options for IBS 
Pharmacological treatment: 
• IBS-D: Antimotility agents like loperamide, 5-HT3 receptor antagonists like Ondansetron, 
Eluxadoline, Cholestyramine (in those who suffer from bile acid malabsorption) 
• IBS-C: Laxatives, Linaclotide, Lubiprostone, Prucalopride 
• Abdominal pain: Peppermint oil, antispasmodics drugs, antidepressants (like selective 
serotonin reuptake inhibitors (SSRIs) and Trycyclic antidepressants (TCA)) 
• Bloating: Rifaximin, Simethicone 
Psychological interventions: 
• Stress management/relaxation therapy 
• Cognitive behavioral therapy (CBT) 
• Psychodynamic therapy 
• Hypnotherapy 
Lifestyle advice:                                                                                                                    
Guidance for self-help to cope with IBS by: 
• General lifestyle 
• Physical activity 
• Diet 
• Symptom-based medication 
Dietary interventions: 
• Traditional dietary advice/general dietary advice (NICE guidelines) 
• Gluten-free diet 
• Low FODMAP diet 
• Review amount and type, and possibly adjust the fiber intake  
• Soluble fiber (like psyllium) 
• Probiotics 
• Fluid intake 
Figure 5: Treatment options for IBS, with data based on (8, 15, 26, 27, 41).  
 
1.3 The low FODMAP diet 
The abbreviation FODMAPs stands for fermentable oligosaccharides, disaccharides, 
monosaccharides and polyols (16). Oligosaccharides include galactans 
(galactooligosaccharides-GOS), which can be found especially in legumes, and fructans 
(fructooligosaccharides-FOS and inulin) found in, among others, onions, garlic, rye and wheat 





and yoghurt etc. Monosaccharides consist in this context, of fructose when it is in excess of 
glucose, and this is present in fruits like apple, mango and pear (42). Finally, there are 
polyols, such as sorbitol, mannitol, maltitol, xylitol, erythritol, isomalt and so on, which are 
both found naturally in fruits and vegetables like apple and celery, and also used as 
sweeteners, and are for example present in sugar-free chewing gum (42). 
 
1.3.1 Mechanisms and evidence basis 
The mechanisms behind this heterogeneous group consisting of short-chain carbohydrates 
start with malabsorption of the FODMAPs in the small intestine (16, 42, 43). This leads to a 
rise in osmotic action which in turn causes more water content in the lumen of the small 
intestine, and also causes the small intestine to distend (16, 42, 43). Undigested FODMAPs 
along with increased water content goes on to the large intestine and can be fermented by 
microbiota to short-chain fatty acids which in turn will lead to gas production (16, 42, 43). All 
of this can lead to a distension of lumen of the large intestine, as well as result in different 
IBS-like symptoms, such as bloating, discomfort/pain, excessive flatus, alterations in bowel 
habits and lethargy (16, 42, 43). These mechanisms were proved to be supported by a 
randomized intervention study including twelve patients with ileostomy that tested this 
hypothesis (44). They found that when the participants followed a high FODMAP diet, they 
had a larger proportion of fermentable substrates as well as increased water content out of 
ileum, compared to when they followed a low FODMAP diet (44).  
 
A recent meta-analysis showed that following a low FODMAP diet led to both a significant 
reduction in IBS-SSS score and a significant enhancement in IBS-QOL score (16). In the 
RCT studies that had been included, it was also found a significant improvement in typical 
gastrointestinal symptoms such as abdominal pain and bloating, as well as overall symptoms, 
at a low FODMAP diet (16). This meta-analysis and other review articles support and/or 
conclude that it is enough evidence to determine that the low FODMAP diet is effective in the 
treatment of IBS symptoms (8, 16, 41-43, 45, 46). A recent review article suggested that as 
much as up to 86% of the patients suffering from IBS, experience an improvement in IBS 





following the diet (46). The article also emphasized that the potential effect may be dependent 
on dietary adherence and by dietary guidance of specialized clinical dietitians (46). 
 
There have been conflicting results when the effect of low FODMAP diet has been compared 
to the effect of traditional IBS diet advice. An RCT study showed that traditional IBS diet 
advice based on both NICE and BDA guidelines, decreased IBS symptom similar to a low 
FODMAP diet (35). While for example two other studies and another meta-analysis showed 
that the low FODMAP diet was more effective in improving symptoms, when compared to 
standard dietary advice based on the NICE guidelines (47-49). 
 
1.4 Self-management/patient education 
Self-management is simply explained by "helping people to help themselves" (50), so that 
they can improve the way they deal with their struggles, and in this case cope with IBS better 
(26, 50). This includes qualified patient education, where they can learn about their condition, 
as well as being motivated and inspired to take care of themselves in the best possible way 
(50). This involves both a collection of tools and techniques that can make it easier to choose 
the healthiest lifestyle, and at the same time build up a good collaboration between the patient 
and the therapist (50). Motivation to healthy eating habits, physical activity, safeguarding 
mental health, guidance in the use of pharmaceutics, in addition to managing worsening of 
symptoms and gaining knowledge to know when it is necessary for professional help, are 
some key words for help to self-care (50). A review article suggested on the background of 
high quality studies and descriptive overviews, which together accounted for more than 550, 
that such "self-management support designed to increase self-efficacy can have a positive 
impact on people's clinical symptoms, attitudes and behaviors, quality of life and patterns of 
healthcare resource use" (50). Another, smaller systematic review article, which had included 
eleven studies with all together 1657 IBS-patients, also concluded that self-management 
support can be beneficial for this group of patients (51).   
 
A study by Joc et al (52) also support these findings. They assessed the quality of life in 83 
IBS patients before and after the patients were educated with information about the disease, 





The participants got guidance from doctor and nurse, individually at the outpatient clinic, and 
they also received written information as well. Joc et al concluded that the education 
significantly improved the quality of life and significantly reduced the patients’ IBS 
associated complaints, and that education is central in the treatment of IBS patients (52). 
 
1.5 Internet-based treatment 
There is limited research on web-based treatment of IBS patients, assembled by a 
gastroenterologist, physiotherapist, psychiatrist and a clinical dietitian, such as the 
intervention in this Master's thesis. But one example is a pilot study where 40 IBS patients 
were recruited for an internet-based self-management program, lasting for 12 weeks (53). The 
results showed no significant improvement in self-efficacy or quality of life, but self-reports 
showed that information given about IBS lead to a significantly increased knowledge about 
the disorder, within the participants (53). Various studies have also shown that internet-based 
cognitive behavior therapy (ICBT) can have a positive effect on IBS patients (54-57), both at 
enhancing IBS-like symptoms and quality of life (54, 56), but also at being a cost-effective 
treatment (55). Another RCT study concluded on the background of the 143 IBS-patients 
participating, that “structured patient group education (IBS school)” is a better alternative than 
written information, in the treatment of IBS (58). This was based on the results where they 
found that the IBS school gave the participants a greater insight and knowledge about IBS, as 
well as it enhanced the IBS-like symptoms and IBS-related anxiety to a greater extent (58). 
These limited but uplifting, and somewhat mixed findings requires further research, to 
identify more of the potential effect, internet-based treatment can have on IBS patients. 
 
1.6 Objective  
The objective with this master thesis was to develop the educational content of the eHealth 
program, as well as creating and implementing the content into Checkware's technical 
platform, in cooperation with Helse Bergen - Section for eHealth. A separate electronic 
platform for control group 1 was also created in cooperation with Helse Bergen. Finally, 
patients were recruited to the pilot study. The primary aim of the study was to evaluate 
whether the eHealth program could be effective as a healthcare measure. This was assessed 





symptoms and health-related quality of life, from baseline to after 3- and 6 months. 
Intermediate aim 2 was to assess the possible improvement in symptoms and quality of life in 
the control groups, and compare the improvements of the eHealth program with the two 





























2. SUBJECTS AND METHODS 
 
2.1 The study 
The study was a prospective, open, pilot study, where quantitative methodology was used for 
analysis. The study was initiated by National Centre of Competence in Functional 
Gastrointestinal Disorders (NKFM) at the Department of Medicine, at Haukeland University 
Hospital. The study was conducted by the above in cooperation with the faculty of Medicine 
and Dentistry at the University of Bergen. 
 
2.2 Planning of the project 
The project idea about an internet-based school was initiated by Birgitte Berentsen, the 
project manager of the school, and was applied for and received financial funds the first time 
in May 2015. Subsequently, a project work-, medical specialist, and supervision group, as 
well as international partners were established to be responsible for each of their tasks. During 
autumn 2015 and spring 2016, the professional content was developed and implemented in 
Checkware’s technical platform by Helse Bergen- Section for eHealth, among other tasks. 
 
Regional Committee for Medical and Health Research Ethics (REC), approved the main 
application of the project protocol which had been compiled by Birgitte Berentsen, September 
the 5th 2016, with the REC number 2016/1098 (appendix 1 and 2). New request to include a 
15-year-old in the project was sent, and a new REC approval with the alterations was received 
October the 13th 2016 (appendix 3). We also applied for an inclusion of 100 patients in the 
control group, and we got REK approval for this 07.12.2016 December the 7th 2016 (appendix 
4). 
 
The author of this master thesis was assigned to the project in January 2016. The educational 
content in the eHealth program was further developed and improved from August 2016, until 
start-up, by clinical dietitians Ingrid Skjold, Mari Folden Oppegård and the author of this 
thesis. The participants were recruited in September 2016, whereas the internet-based school 





regular IBS school at LMS were included in the study between March and September 2017. 
Control group 2 contained patients who participated at an extended IBS-school at LMS in 
October 2015. 
 
2.3 Recruitment of patients 
Patients in the study group were recruited from the waiting list of the IBS-school at learning 
and mastering centre (LMS) in Bergen. Patients included had been diagnosed with IBS and 
referred to this school by their general practitioner (diagnostic code D93) or specialist in 
gastroenterology (diagnostic code K58). Comorbidities were not controlled for, and were not 
a reason for exclusion. All participants were contacted by phone, by healthcare professionals, 
affiliated with the project. Exceptions were one of the patients, who was recruited directly 
from an appointment with his specialist in gastroenterology and one patient who was recruited 
directly from the project leader. 52 patients fulfilled the inclusion criteria and where therefore 
included in the study. 40 of these patients completed the 3 months evaluation, and 31 
completed the 6 months evaluation. 
 
An age range in the study group, between 18-70 was set. The upper age limit was set to 
ensure compliance, as older people are more likely to experience technical difficulties with an 
internet-based school, compared to younger people with more internet experience. We sat a 
lower limit of 18, as the professional content is not designed for a pediatric view. There was 
also technical challenges, supporting the lower limit of 18, as the legislation has an age limit 
of 15 to get a Bank-identification (BankID) (59), which is necessary to log into the internet-
based school.  We still chose to include one patient at the age of 15, with a motivated mother 
also suffering from IBS, who could log in with her BankID-number on behalf of the patient.  
The same age range (18-70) was set in control group 1, while data from control group 2 were 









Table 1: Inclusion and exclusion criteria in the study group 
 




The eHealth program is a guided self-help intervention program where the participants learn 
how to cope with their disease, based on quality assured information. Figure 5 shows the 6-8 
weeks’ program and how it is designed in an interdisciplinary manner, separated into 5 
modules. The educational content is presented through text, images, videos, animation and 
home based assignments. Module 1 consists of among other things, an introduction about IBS 
by gastroenterologist Trygve Hausken, and further more detailed information about the 
functioning of the gastrointestinal tract and what IBS is. In Module 2, the physiotherapist, 
Eirik Østvold, introduces, among other things, proper body awareness and posture, and how 
to achieve proper breathing techniques. The content presented by the clinical dietitian Synne 
Ystad, in Module 3, contains lifestyle and simple dietary advice based on NICE guidelines. 
Module 4 consists of among other things, an introduction to cognitive therapy by psychiatrist 
Jørn Bødtker. Furthermore, it presents how body and mind work together and the participant 
Inclusion criteria Exclusion criteria 
• Got the IBS diagnostic code from either  
their general practitioner (D93) or by a                                             
specialist in gastroenterology (k58) 
• Participants between 18-70 years of age 
• Written consent form 
• Completed baseline questionnaires (both 
by post and electronically)  
• Pregnancy 
• Surgery affecting the gastrointestinal 
tract, during the study 
• Attending the IBS-school at LMS 
during the course of the study 
 
 
Inclusion criteria Exclusion criteria 
• Got the IBS diagnostic code from either  
their general practitioner (D93) or by a                                             
specialist in gastroenterology (k58) 
• Written consent form 
• Completed baseline questionnaires (both 







will learn about mindfulness and eventually be introduced to exposure therapy. In Module 5, 
participants get supervised through the dietary intervention of the low FODMAP diet by 
clinical dietitian Synne Ystad. Together with clinical dietitian Ingrid S. Skjold they present 
inspirational and motivational cooking films (Appendix 5 contains a low FODMAP diet 
brochure, which is a compressed version of Module 5 in the internet-based gastrointestinal 
school). The participants could go through the internet-based school in their own speed and 






































Figure 6: Overview of the timeline for the course of the study. The yellow boxes represent the study 
group participating in the eHealth program, the blue boxes represent control group 1 participating in 
the IBS-school at LMS.  
 
2.5.1 Study group 
Prior to the intervention: The patients who had been referred to the IBS-school at LMS 
from their GP or specialist in gastroenterology, were given a phone call, to be offered to 
participate in this pilot study. Those who wanted to attend to the eHealth program, were 
invited to an information meeting about the internet-based school. The project leader, as well 
as those who had contributed to the academic content, such as clinical dietitians, 
gastroenterologist, psychiatrist and the master student in clinical nutrition, also came and 
presented the content of the module they had been professionally responsible for. The 
participants were also informed about ethical considerations, and the patients who wanted to 
participate filled out the content form to be included in the study (appendix 5). The patients 
who didn’t have the opportunity to come to the information meeting, got the necessary 
information equivalent to the meeting, in the post, including the information and content form 
they could fill out and send back in the post (appendix 6 contains the additional write with 





Due to the license delay of the IBS-SSS and Rome III criteria questionnaires, these could not 
be electronically developed in Checkware’s platform and were sent by the post, while the four 
other questionnaires RAND-36, HADS, HBNKFM and IBS-QOL were developed and 
completed by the participants electronically. This was the case both at startup and at 3 
month’s evaluation, while within 6 month’s of evaluation, all questionnaires were developed 
electronically, which is shown in Table 3. When the participants had signed written consent, 
and completed both the baseline questionnaires sent by post and electronically, they got 
access to the IBS eHealth program (MT-skolen). 
eHealth program: The duration of the eHealth program was individual for each participant, 
but the assumed time use was in advance about 6-8 weeks. The study in total lasted for 6 
months. The study participants had the opportunity to ask, clinical dietitian Mari F. Oppegård 
and the student in clinical nutrition, questions related to the program during the whole 
intervention, especially nutrition-related questions. 
After the intervention: To evaluate the effect of the eHealth program, the participants 
completed medical questionnaires before start-up, and 3- and 6 months after the start of the 
internet-based school. These questionnaires were based on their quality of life and symptoms 
associated with IBS. The differences in the measurements before and after the eHealth 
program were evaluated, to see whether the program had a significant effect on participants or 
not. After the intervention, all the patients who had participated in the eHealth program, were 
invited to an evaluation meeting. Here they had the opportunity to provide feedback regarding 
the program, as well as meeting the same professions as from the information meeting, and 
having the possibility to ask any professional questions regarding things that were unclear in 
the content. 
 
Table 3: Overview of the timetable for the various medical questionnaires in the study group. 
Baseline questionnaires 3 months’ questionnaires 6 months’ questionnaires 
By post: By post: By post: 
IBS-SSS 
Rome III criteria  
IBS-SSS 
Rome III criteria 
 




















2.5.2: Control groups 
Control group 1:  
In addition to evaluate the effect of the eHealth program in itself, we wanted to compare it to 
the effect of the current program for the IBS-patients, the two-day physical IBS-school at 
“LMS”. Three regular schools, each in April, May and June 2017 were used as control group 
1, which got the same questionnaires as used in the eHealth program. The patients were 
offered to be a part of the control group when they physically attended to the IBS-school at 
LMS. If they wanted this, they got information about the study, and ethical considerations and 
finally filled out consent form and got registered for the study. The IBS-school in April got 
two of the baseline questionnaires by hand, due to license delay, but received the 3-month’s 
evaluation electronically. Both the schools in April and June, got all the questionnaires 
electronically, as shown in Table 4. The effect of the physical IBS-school at LMS, when 
looking at the differences in the measurements between the baseline and 3-month’s 
evaluation, where compared with the same differences between baseline and 3-month’s 
evaluation in the eHealth program.  
 
Control group 2: 
Unfortunately, there wasn’t enough time to get the 6 months’ evaluations from the IBS-school 
in April, May and June 2017 in this master thesis, therefore control group two is based on 
earlier data. The participants in control group 2 completed questionnaires when they attended 
a two-day extended IBS-school at LMS in October 2015, and got the same questionnaires in 
the post 6 months after the school. These participants obviously didn’t complete all the 
questionnaires as in the eHealth program, but only NKFM, Rome III criteria and IBS-SSS, as 
shown in Table 5. The effect of the extended IBS-school at LMS, when looking at the 
differences in the measurements between the baseline and 6-month’s evaluation, where 
compared with the same differences between baseline and 6-month’s evaluation in the 









Table 4: Overview of the timetable for the various questionnaires in control group 1. 
 Baseline questionnaires 3 months’ questionnaires 
IBS-school at LMS in April 
2017: 
By hand: By post: 
 IBS-SSS 
Rome III criteria 
 














































Table 5: Overview of the timetable for the various questionnaires in control group 2. 
 Baseline questionnaires 6 months’ questionnaires 
 By hand: By post: 
Extended IBS-school at LMS in 
October 2015: 
NKFM 
Rome III criteria 
IBS-SSS 
NKFM6 




2.6 Questionnaires used 
The standardized questionnaires used in this study were selected questions from Rome III 
Diagnostic Criteria for Functional Gastrointestinal Disorders (Rome III-criteria), Irritable 
Bowel Syndrome-Quality of Life questionnaire (IBS-QOL), Irritable Bowel Syndrome 





RAND-36 Measure of Health- Related Quality of Life (RAND-36). The questionnaires were 
sent to the participants and were asked to be filled out, before the start of the eHealth 
program, as well as 3 and 6 months after the start-up.  
 
National Centre of Competence in Functional Gastrointestinal Disorders (NKFM) forms were 
used in three different versions relative to the time of the study; HBNKFM0, HBNKFM3 and 
HBNKFM6. Client satisfaction questionnaire (CSQ-8) was added to the 3 months evaluation. 
Due to approved license to use, the questionnaires IBS-QOL, HADS, RAND-36 and NKFM 
were completed by patients electronically, while Rome III and IBS-SSS were sent to the 
patients by mail, at baseline and after 3 months. At 6 months, all data collection was carried 
out electronically. All the data are subjective, which leads to the questionnaires giving raw 
data that are based on patient-reported outcome (PRO). 
 
2.6.1 Rome III criteria (appendix 7) 
The Rome III Diagnostic Criteria for Functional Gastrointestinal Disorders were developed in 
2006 by the Rome foundation, with the aim of having a classification system of the disorders 
that could be used both in research and clinical care (1). The process with the Rome III 
criteria extends over a 15-year long period, from the beginning with Roma I to Roma II and 
now the latest modifications and updates in Roma III (1).  
 
Rome III consists of, criteria for diagnosing Functional Gastroduodenal Disorders (e.g. 
functional dyspepsia) and Functional Bowel Disorders (e.g. IBS) (1, 7, 60). In the study, 34 
questions from these Criteria were selected to confirm which of the patients had IBS and what 
subgroup they possibly belonged to, according to Rome III, after being given the IBS 
diagnosis by their GP/gastroenterologist. The Rome III criteria would also confirm who had 
either IBS-like symptoms and/or symptoms related to functional dyspepsia and if they 








2.6.2 Irritable Bowel Syndrome – Quality of Life Measure (IBS-QOL appendix 8) 
IBS-QOL is a health-related quality of life (HR-QOL) questionnaire, compiled to measure 
how and in what grade IBS and the treatment of its symptoms affects these patients’ quality of 
life (61-63). IBS-QOL has been confirmed to be a validated questionnaire with high 
consistency and high reproducibility (61-63). The questionnaire comprises of 34 questions, all 
with the same response scale 1-5; “1. Not at all, 2. Slightly, 3. Moderately 4. Quite a bit 5. 
Extremely/A great deal” (63). The scoring system is calculated as demonstrated in fig 7 
below. IBS-QOL consists of eight subscale scores; dysphoria (8 questions), Interference with 
Activity(7 questions), Body Image (4 questions), Health Worry (3 questions), Food 
Avoidance (3 questions), Social Reaction (4 questions), Sexual (2 questions), and 
Relationships (3 questions)” (63). The transformation of the score gives a possible range score 
between 0-100, where 0 indicates poor quality of life, whereas 100 indicates maximum 




Figure 7: The transformation formula used to calculate the total and the eight subscale scores for IBS-
QOL. Patrick et al. A Quality-of-Life Measure for Persons with Irritable Bowel Syndrome (IBS-QOL): 
User’s Manual and Scoring Diskette for United States Version.  University of Washington, 2007 (63).   
 
2.6.3 IBS-SSS (appendix 9) 
IBS-SSS is a validated and standardized questionnaire used to assess the severity of the 
patient’s IBS-symptoms (24). The form consists of five questions concerning severity of 
abdominal pain, frequency of abdominal pain, severity of distension, satisfaction with bowel 
habits and the symptoms’ interference on the patient’s life in its entirety. Each of the 
questions can give a value from 0 to 100, by utilizing a 100-point visual analogue scale 
(VAS), which can give a possible total score between 0-500 (24).  
The severity of the symptoms is categorized, based on the total score, into mild (75-175), 
moderate (175-300) and severe (>300), while a score less than 75 considers the patient as in 
remission(24). A reduction in the score by at least 50, indicates a significant clinical 





2.6.4 HADS – Hospital Anxiety and Depression scale (appendix 10) 
HADS is a validated questionnaire that was developed in 1983 by Sigmond and Snaith, with 
the aim of identifying if patients in non-psychiatric hospital clinics, suffered from anxiety 
disorders and/or depression (64, 65). The questionnaire is a cost-effective screening tool and 
is used largely both for research and in clinical practice, and despite the questionnaire's "tittle" 
it's also been validated when it has been implemented in community settings and primary care 
medical practice (64, 66, 67). The questionnaire consists of  a total of 14 items, of which 7 of 
them constitute the subscale depression, and the remaining 7 constitute the subscale anxiety  
(68). Each question can give a value from 0 to 3, which can give a possible total score 
between 0-21 for both depression and anxiety, separately (67). The severity of the patient’s 
mood state is categorized, based on the total score of each of the two subscales into normal 
/non-case (0-7), mild (8-10), moderate (11-14) and severe (15-21) range (67, 68). The cutoff 
score for HADS total is a score of 16 or above (65, 69). 
 
2.6.5 The RAND-36 Measure of Health-Related Quality of Life (HRQoL) (RAND-36) 
(appendix 11) 
RAND-36 is possibly the most widely used questionnaire applied to assess a person’s quality 
of life, based on their health (70). This means how the health effects a person’s mental, 
physical and social life, and also how it influences his/her functioning in everyday life (70).  
RAND-36 consists of 36 questions which are identical to SF-36 which was customized based 
on the medical Outcomes Study (MOS) (1, 70). The Knowledge Center for Health Services at 
the Institute of Public Health translated RAND-36 into Norwegian which is used in this thesis 
(71).  
 
The 36 questions are divided into eight categories; “physical functioning (10 questions), role 
limitations due to physical health (4 questions), role limitations due to emotional problems (3 
questions), energy/fatigue (4 questions), emotional well-being (5 questions), social 
functioning (2 questions), pain (2 questions) and general health (5 questions)”(1, 70). In 
addition, there is one single question which constitutes the category “health change”. The 






2.6.6 National Centre of Competence in Functional Gastrointestinal Disorders (NKFM) 
(appendix 12-16) 
The questionnaires NKFM0 (appendix 12) and NKFM6 (appendix 13) was made by National 
Centre of Competence in Functional Gastrointestinal Disorders with the purpose of being 
used as evaluation forms for the IBS-school at LMS. The forms also allowed gathering of 
self-reported medical history and general medical information such as age and sex. NKFMO 
was filled out by the patients when they attended the IBS-school, and NKFM6 was sent in the 
post and filled out by the patients 6 months later. In cooperation with clinical dietitian Mari 
Folden Oppegård, the researcher developed three other versions of the original form, 
HBNKFM0 (appendix 14), HBNKFM3 (appendix 15) and HBNKFM6 (appendix 16), used at 
the start, and 3- and 6 months after the start-up in the eHealth program, respectively.  
 
NKFM0 consists of 14 questions which give a broad view about the patient’s background and 
disease history. NKFM6 consists of 7 questions, whereas 2 of the items are about the patient’s 
background, 2 items contain questions about the low FODMAP diet, and 3 questions concerns 
the patient's assessment and experience of the IBS school. 
 
HBNKFM0 consists of 18 questions, in addition to 2 sub questions, where the first 16 items 
are identical to the questions from the original NKFM0. The next 2 questions and 2 sub 
questions about their experience of the low FODMAP diet are modified to ease the 
comparison to 3- and 6 months. HBNKFM3 contains 22 questions, in addition to 5 sub 
questions. The first 16 items consisting of the patients’ background and history are identical to 
the original form, whereas the next question and 5 sub questions about the low FODMAP 
diet, are formatted related to the time in the study. This questionnaire also includes 5 
questions related to the participant’s degree of satisfaction with the different modules. The 
different response options were “not at all”, “slightly”, “moderately”, “quite a bit” and “a 
great deal”. HBNKFM6 contains 12 items, where the questions about the patients’ history of 
illness are cut down to 1 item, whereas the 1 question and the 5 sub questions about the low 
FODMAP diet, are reformatted related to the time in the study. The 5 remaining questions are 






2.6.7 CSQ-8 Client Satisfaction Questionnaire (appendix 17) 
The validated Client Satisfaction Questionnaire (CSQ-8), was originally developed in 1979 by 
Larsen, Attkisson, Hargreaves and Nguyen (72, 73). The questionnaire consists of 8 items in 
addition to 2 open-ended questions, which we utilized with the purpose of it being a useful 
measure of the patient’s satisfaction and experience of the service, as well as getting their 
feedback on the eHealth program (73). Each question can give a value from 1-4, where “1” 
reflects the lowest level of satisfaction, and “4” reflects the highest, which can give a total 
score between 8-32 (72, 73). 
 
2.7 Hypothesis 
The intermediate aim 1 of the study was to evaluate whether the eHealth program is effective 
as a healthcare measure, by comparing quality of life and IBS-related symptoms, before and 
after the eHealth program. Intermediate aim 2 of the study was to assess the effect of the 
current program, the physical IBS school at LMS, by comparing differences in quality of life 
and/or IBS-related symptoms, before and after the school. Finally, the effect of the eHealth 
program was compared to the effect of the physical IBS school on LMS.  
 
Null hypothesis H01: The study participants will not experience any differences in quality of 
life and IBS-related symptoms after participating in the eHealth program.                    
Alternative hypothesis Ha1 (two-sided) The participants will experience differences in quality 
of life and/or IBS-related symptoms after participating in the eHealth program.  
 
Null hypothesis H02: The study participants will not experience any differences in quality of 
life and IBS-related symptoms after participating in the physical IBS-school at LMS.                                                                                                                           
Alternative hypothesis Ha2 (two-sided) The participants will experience a difference in quality 










There was no extra cost associated with participating in this study. Attendance at information- 
and evaluation meeting was not a requirement to participate in the study, and travel fees were 
covered for those who came from the area outside of Bergen. Parking fees at Haukeland 
University Hospital were covered for all the participants.  
 
2.9 Ethical considerations 
The study was approved of the Regional Committee for Medical and Health Research Ethics 
(REC), REK vest, in September 2016. All the participants gave informed, written consent. 
The participation was voluntary, which meant that the participants could withdraw at any time 
during the study, without any justification. The study was considered as harmless for the 
participants, and all data was collected unidentifiable and was treated confidentially. A 
research server / security group was created, where sensitive data was stored, and only people 
associated with the research project had access to this security group. It was also created a 
separate area for storing the link key between the person and the ID number, which only the 
project manager had access to.  
 
In order to get a secure electronic identification when participants log in to the IBS eHealth 
program, the login method was chosen to correspond to security level 4, which is the highest 
level of security (74, 75). This means that the participants can login with either of the 
following login methods; Bank identification on a memory stick or mobile, Buypass on a 
smart card or mobile, or Commfides.  
 
2.10 Statistical analysis 
The raw data from the questionnaires sent and returned by post (IBS-SSS and Rome III 
criteria) were plotted in the program “FileMaker Pro Database 15”, and then the records were 
exported to Microsoft Excel. The raw data from the electronical questionnaires (RAND-36, 
HBNKFM -0,3,6, CSQ-8, HADS, IBS-QOL and at the 6 months evaluation also IBS-SSS and 
Rome III criteria) were directly exported to SPSS files. Statistical analysis of all data was 





Descriptive statistics were conducted on different variables in the questionnaires to identify 
e.g. frequencies, means, standard deviation and normal distribution. All the data were checked 
for the latter, by using the normality tests Kolmogrov-Smirnov and Shapiro Wilk test in 
SPSS. 
 
On parametric distributed data, paired t-test, unpaired t-tests and repeated measures one-way 
ANOVA were run. In the analysis of data from the eHealth program, paired t-tests like paired-
Samples t-test and repeated measures one-way ANOVA were used, as the data was 
measurements from different time points, but from the same patients. In the analysis of the 
data from control group 2; the extended IBS-school at LMS, unpaired t-test like summary 
independent-samples T-test were used. This because the data consisted of measurements from 
different time points on unequal groups. Nonparametric data from the eHealth program were 
analyzed by Wilcoxon matched-pairs signed rank test, because as mentioned, the data was 
from measurement of equal groups.  
 
These tests were used to compare the mean of the measurements at the three different time 
points, baseline and after 3- and 6 months, to investigate if there was a statistically significant 
difference between them. The tests were not supplemented with a multiple comparisons test, 
but the actual p-values were reported. This requires a more critical view on the p-values that 
are just below 0.05. Correlation analysis between IBS-SSS sum score and IBS-QOL overall 
score were performed at baseline and after 3- and 6 months, using Pearson correlation test. 
P-values <0.05 were regarded statistically significant. All the reported P-values are based on 
two-sided tests. The normally distributed data are illustrated in simple bars with data reported 
as mean (SD). All values given as the latter are mean ± 1 standard deviation. Where the data 
is not normally distributed and a nonparametric test is performed, the data are illustrated in 











3.1 Patient recruitment, responses and demographics 
63 patients agreed to attend the study, whereas 57 submitted written consent form and 
returned the completed questionnaires sent by post. These patients got access to the internet-
based gastrointestinal school, and before start-up they were supposed to complete the four 
electronical questionnaires. Only 52 of the participants completed these questionnaires and 
were therefore included in the study, which is shown in Figure 8, and the rest of the patients 
were excluded. Six of these participants were excluded during the course of the study. One 
because of pregnancy, two got operated, two attended the IBS-school at LMS during the 
study, and one of the patients withdrew from the pilot study. 46 of the attendants were asked 
to fill out the questionnaires at the 3 months evaluation, whereas 40 of the participants 
completed either the electronical questionnaires or the questionnaires sent by post. 31 of the 
patients completed the questionnaires in the 6 months evaluation.  
 
Because of a high drop-out rate during the program, analyze (I) is based on the 31 participants 
who completed the 6 months evaluation, which is called eHealth program (I). Analyze (II) is 
based on the 40 patients who completed the 3 months evaluation, which is called eHealth 
program (II). n varies slightly from questionnaire to questionnaire. Figure 9 shows that most 
of the included participants were recruited by phone, among those who already had been 
















Recruitment of study participants
Recruited from the
waiting list for IBS
school at LMS (n=50)
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Figure 8: A flow chart over the recruitment and the patient responses by May 28, 2017. 40 patients 
completed the eHealth program and completed the 3 months’ evaluation, whereas 26 of the patients 


















3.2 Results from the participants who completed and responded the 6 months 
evaluation; eHealth program (I) 
The first analyze (I) of the eHealth program, have assessed the mean and individual responses 
of the 31 study participants who completed the entire eHealth program and responded to the 6 
months evaluation. Some of the participants have not completed all of the questionnaires, so n 
will vary from form to form. 
 
3.2.1 Study population and baseline characteristics 
Baseline characteristics of the 31 that completed the 6 months evaluation (eHealth program 
(I)), are compared to the 52 patients included in the study, in Table 6. 
 
Table 6: Baseline demographic of the 52 patients included in the study, compared to the 31 that 








eHealth program (I) 







Female/male 36/16 23/8 19/7  
Mean age (range), years 37.6 (15-66) 38 (20-56) 36.9 (20-56)  
Severity of symptoms 














n = 5 (10%) 
n = 23 (44%) 
















n = 2 (8%) 
n = 13 (50%) 


































1 = Total included in the study vs eHealth program (I) 






3.2.1.1 Gender and age 
Among the 52 included participants in the study, 36 were female (69%). Of the 31 patients 
who completed the 6 months evaluation and are hence a part of the eHealth program (I), 23 
were female (74%). The mean age among the 52 included was 37.6 years (range, 15-66 y), 
and among the 31 in the eHealth program (I) it was 38.0 (20-56).  
 
3.2.1.2 IBS severity 
Table 6 shows baseline mean IBS-SSS sum score for the 52 study participants included in the 
study, as well as for those who completed the 6 months evaluation; eHealth program (I). 
Because of missing data on this questionnaire, eHealth program (I) contains only 26 (n) 
participants. The score for the 52 included in the study was 296.8 (range, 145-500), while it 
was 282.5 (range, 160-500) for eHealth program (I), but the difference wasn’t statistically 
significant (p=0.490). The distribution of the IBS severity was for the 52; mild=5 (10%), 
moderate=23 (44%), severe=24 (46%), and for the eHealth program (I); mild=2 (8%), 
moderate=13 (50%) and severe=11 (42%). 
 
3.2.1.3 IBS-QOL 
The baseline mean IBS-QOL overall scores for the 52 study participants included in the study, 
and for those who completed the eHealth program (I) were 45.8 and 50.0, respectively (Table 
6). The difference was not statistically significant (p=0.333). Due to missing data on this 
questionnaire, eHealth program (I) contains of 30 (n) participants, instead of 31.  
 
3.2.1.4 ROME III criteria 
Based on the ROME III criteria 29 (55.8%) of the 52 participants included in the study, would 
get the IBS-diagnosis at baseline, and 2 (3.8%) wouldn’t (Table 6). It also shows that there 
was insufficient information on 21 (40.4%) of the study participants, due to misinterpretations 
of the questionnaire. For the 31 participants who completed the 6 months evaluation (eHealth 
program (I)), 21 (67.7%), 0 (0%) and 10 (32.3%), would get, not get and had insufficient 






3.2.2 The control groups and their baseline characteristics 
In control group 1, there were 20 patients that were recruited from the IBS-school which 
fulfilled the baseline and the 3 months questionnaires. In control group 2, 71 patients were 
recruited from the IBS school and filled out the baseline questionnaires, but only 32 of them 
filled out the 6 months questionnaires. 
 
Table 7: Baseline demographic of the participants in control group 1 and 2. 
PARTICIPANTS Control group 1 (n=20) Control group 2 (n=71) 
Female/male 17/3 59/10 (missing data; 2) 
Mean age (range), years 45 (33-68) 35.8 (15-67) (missing data;1) 
Severity of symptoms 







3.2.2.1 Gender, age and IBS severity 
Of the 20 participants in control group 1, 17 (85%) of the were women (Table 7). The average 
age was 45 years (range, 33-68 y), and the IBS severity mean score at baseline was 286.8. Of 
the 71 patients included in control group 2 at baseline, 59 (86%) were women. The average 
age was 35.8 (range, 15-67), and the IBS severity mean score at baseline was 298.0.    
 
3.2.3 Changes during the eHealth program (I); differences between baseline, 3- and 6 months 
 
3.2.3.1 IBS-QOL 
We were interested in assessing whether the participants would experience an improved 
health-related quality of life (HRQOL), according to IBS-QOL, during the eHealth program, 
by comparing the scores at baseline and 3- and 6 months after the start of the school.  
 
Table 8 shows a statistically significant enhancement between baseline and 3 months after the 
start-up, in IBS-QOL overall score (p=0.001) and in the five subscale scores; food avoidance 





and social reaction (p=0.039). When comparing the scores between baseline and 6 months 
after the start-up, it showed a statistically significant improvement in IBS-QOL overall score 
(p=0.00003) and in seven out of eight subscale scores; body image (p=0.048) food avoidance 
(p=0.045), health worry (p=0.003), interference with activity (p=0.0001), dysphoria 
(p=0.000002), relationships (p=0.009) and social reaction (p=0.036). The subscale score 
“sexual” showed a numerically higher score at 3 and 6 months when compared to baseline, 
but neither of these differences were statistically significant. 
 
We also wanted to compare the scores differences between baseline and 3 months, baseline 
and 6 months, and also between 3 and 6 months to look at the whole development during the 
eHealth program. In this way, we could investigate whether the participants continued to 
benefit from the eHealth program after passing 3 months until reaching 6 months after the 
start-up. When looking at these three scores all together it showed that IBS-QOL overall score 
and five of the subscale scores (body image, health worry, interference with activity, 
dysphoria, relationship and sexual) had numerically higher scores at 3 months compared to 
baseline, and even higher numerical scores at 6 months compared to 3 months. But neither of 
these values were statistically significant, when comparing the scores between 3 and 6 
months. Figure 10 and 11 illustrate mean (SD) or median (IQR) for IBS-QOL overall score 
and the eight subscale scores, for the participants who completed the 6 months evaluation (I), 














Table 8: IBS-QOL overall score (0-100) and the eight subscale scores (0-100) for the participants in 
the eHealth program (I), at baseline and 3- and 6 months after the start of the program. Values are 
reported as mean (SD) / median (IQR), as appropriate.  
 Baseline,  
mean (SD) / 
median (IQR)  
(n = 30) 
After 3 months, 
mean (SD) / 
median (IQR)  
(n = 30)  
After 6 months, 
mean (SD) / 
median (IQR) 




50.0 (19.5) 59.1 (21.8) 60.1 (21.9) 1: p=0.001** 
2: p=0.00003**** 
3: p=0.649 





31.1 (24.4) 39.4 (25.5) 35.8 (25.5) 1: p=0.004** 
2: p=0.045* 
3: p=0.252  
Health Worry 
 





48.2 (22.1) 58.5 (26.2) 61.4 (24.7) 1: p=0.004** 
2: p=0.0001*** 
3: p=0.236 
Dysphoria 50.2 (25.8) 63.5 (26.1) 64.9 (26.8) 1: p=0.0002*** 
2: p=0.000002***** 
3: p=0.619 
Relationships 64.2 (25.2) 69.2 (29.9) 70.0 (26.0) 1: p=0.107 
2: p=0.009* 
3: p=0.795 









1 = Baseline vs after 3 months, 2 = Baseline vs after 6 months, 3= After 3 months vs after 6 months 
P-values are based on paired-Samples T test with mean (SD) (Overall, food avoidance, body image, 
interference with activity, dysphoria, relationships, social reaction) or Wilcoxon matched-pairs signed 
rank test with median (IQR) (health worry, sexual). 




















Figure 10: IBS-QOL overall score for the participants in the eHealth program(I), at baseline and 3- 














































Figure 11: The eight IBS-QOL subscale scores for the participants in the eHealth program(I); food avoidance (A), body image 
(B), Health Worry (C), Interference with Activity (D), Dysphoria (E), Relationships (F), Social Reaction (G) and Sexual (H), at 
baseline and 3- and 6 months after the start of the program. Values are reported as mean (SD) (in simple bars; A, B, D-G) or 







3.2.3.2.1 Mean scores 
Analysis of the symptom scores of the patients participating in the eHealth program (I) was 
performed, to investigate whether there was a significant difference between the symptom 
scores at the three time points; at baseline and 3- and 6 months after the start-up of the school.  
 
Table 9 shows a statistically significant improvement from baseline to after 3 months, in IBS-
SSS sum score (p=0.00004) and in four out of five IBS symptoms; severity of abdominal pain 
(p=0.033), frequency of abdominal pain (p=0.01), dissatisfaction with bowel habits (p=0.012) 
and interference with life in general (p=0.0002). When comparing the scores between baseline 
and 6 months after the start-up, it showed a statistically significant enhancement in IBS-SSS 
sum score (p=0.001), and in three out of five IBS symptoms; severity of abdominal pain 
(p=0.042), dissatisfaction with bowel habits (p=0.016) and interference with life in general 
(p=0.00046). 
 
Some of the scores decreased significant from baseline to 3 months and reduced numerically 
even more from 3 months to after 6 months (IBS-SSS sum score and Q5), but neither of these 
scores between 3- and 6 months were statistically significant (p=0.383 and p=0.448), 
respectively. One of the scores decreased significantly from baseline to after 3 months but 
then remained stable until 6 months after the baseline measurement, p-value (0.676) showed 
no statistically significant difference between the mean score after 3- and after 6 months. The 
rest of the scores decreased significant or numerically from baseline to 3 months, and 
increased from 3 months to 6 months to a significantly lower or numerically lower score than 
at baseline (Q1, Q2, Q3), but neither of these scores between 3- and 6 months were 








Table 9: IBS-SSS sum score (0-500) and the five subscale scores Q1-Q5 (0-100) for the participants 
in the eHealth program (I), at baseline and 3- and 6 months after the start of the program. Values are 
reported as mean (SD) / median (IQR).  
Symptoms Baseline,  
mean (SD) / 
median (IQR) 
 
After 3 months, 









IBS-SSS sum score 
(n=26) 
282.5 (82.5) 218.0 (75.8) 203.7 (108.6) 1: p=0.00004**** 
2: p=0.001** 
3: p=0.383 






36 (14.1) 37.9 (20.0) 1: p=0.033* 
2: p=0.042* 
3: p=0.667 
Q2: Frequency of 
abdominal pain 
(n=18) 
66.7 (27.2) 46.7 (26.3) 60.0 (28.7) 1: p=0.01* 
2: p=0.460 
3: p=0.083 
Q3: Severity of 
abdominal distension 
(n=21) 




with bowel habits 
(n=25) 
70.0 (52.5-98.0) 59.0 (36.0-72.0) 59.0 (34.5-71.5) 1: p=0.012* 
2: p=0.016* 
3: p=0.676 
Q5: Interference with 
life in general (n=25) 




1=Baseline vs after 3 months, 2= Baseline vs after 6 months, 3= After 3 months vs after 6 months 
P-values are based on Wilcoxon matched-pairs signed rank test with median (IQR) (severity of 
abdominal distension, dissatisfaction with bowel habits) or paired-Samples T test / repeated measures 
one-way ANOVA with mean (SD) (IBS-SSS sum score, severity of abdominal pain, frequency of 
abdominal pain, interference with life in general). 

















Figure 12: IBS-SSS sum score for the participants in the eHealth program (I), at baseline, and 3- and 
6 months after the start of the program. Values are reported as mean (SD). 
 
 
3.2.3.2.2 IBS-SSS vs IBS-QOL 
 
Figure 13 illustrates the comparison of the development of IBS-SSS mean sum score from 
baseline to after 3- and 6 months, to the development of the mean IBS-QOL overall score, at 
the same points, in the eHealth program (I). Due to different number (n) of patients in the two 
questionnaires, and to compare the patients pairwise, the total number of patients is reduced to 
a total of 25 from the earlier analysis of the eHealth program (I). The scores are almost 
identical to those of the earlier analysis showed in Table 9 and 10, and the development was 
the same. The IBS-SSS sum score improved significantly from baseline to after 3 months 
(p=0.00006) and significantly from baseline to after 6 months (p=0.0003), with the greatest 
mean difference from baseline to 3 months. The same development was seen in IBS-QOL, 
with a significantly improvement from baseline to both after 3 months (p=0.004) and after 6 
















Figure 13: Comparison of the development of the mean IBS-SSS sum score to the development of 
the mean IBS-QOL overall score, at baseline and after 3- and 6 months (A), along with the different 
values at the three time points with n=25 (B). Values are reported as mean (SD). 
 
3.2.3.2.3 Individual responses 
Figure 14 and Table 10 show the individual responses of the study participants who 
completed the 6 months evaluation in the eHealth program (I).   
Figure 14 illustrates the distribution of IBS-severity at the three different time points; baseline 
and after 3- and 6 months. In the three categories, the proportion changed in mild from 2 (8%) 
to 5 (19%) and further to 6 (23%), at baseline and after 3 and 6-months respectively. The 
proportion change in moderate was from 13 (50%) to 17 (65%) and 12 (46%), and finally in 
severe the proportion change was from 11 (42%) to 3 (12%) and 5 (19%), respectively. The 
proportion of participants in remission changed from 0 at baseline to 1 (4%) after 3 months, 
and 3 (12%) after 6 months.  
Table 10 shows how many of the participants who significantly improved their IBS 
symptoms, according to the IBS-SSS sum score, by reducing the score by at least 50. 11 
(42.3%) out of 26 patients, significantly improved their symptom score from baseline to both 
after 3 and 6 months. 5 (19.2%) of the study participants did not significantly improve their 
symptom score from baseline to after 3 months, but did significantly improve from baseline to 
after 6 months. 4 (15.4%) of the participants significantly improved their score only from 
baseline to after 3 months, but did not contain this score stable enough that there was a 
significant improvement from baseline to after 6 months. Finally, there was 6 (23.1%) 






Of the latter group, there were oppositely, 3 of the participants who did not significantly 
worsen the symptom score from baseline to after 3 months, but did significantly worsen their 















Table 10: Individual significantly improvements in IBS-SSS sum score, of the 26 participants 




Total=26 Yes n (%) 
Significant improvement (reduction by at least 50) from baseline to both after 3- and 6 
months 
11 (42.3%) 
Significant improvement (reduction by at least 50) from baseline to after 6 months, 
but not a significant improvement from baseline to after 3 months 
5 (19.2%) 
Significant improvement (reduction by at least 50) from baseline to after 3 months, 
but not a significant improvement from baseline to after 6 months 
4 (15.4%) 








We were also interested in assessing whether the study participants would experience 
improved anxiety and depression, during the eHealth program, according to the HADS 
questionnaire. This was evaluated by comparing the mean score at baseline and 3- and 6 
months after the start-up of the program (Table 11). Both means of the HADS sum score and 
the subscale scores of depression and anxiety, reduced numerically both from baseline to 3 
and 6 months, with the lowest numerically score after 3 months for all the means, but neither 
of the differences were statistically significant. 
 
Table 11: HADS sum score and the two subscale scores (0-21), for the participants in the eHealth 
program (I), at baseline and after 3- and 6 months. Values are reported as mean (SD). 
 Baseline,  
mean (SD) 
(n = 31) 
After 3 months, 
mean (SD)  
(n = 31) 
After 6 months, 
Mean (SD) 




12.9 (5.9) 11.2 (6) 11.5 (6.8) 1: p=0.063 
2: p=0.087 
3: p=0.662 
Depression 4.7 (3.2) 4.2 (2.9) 4.5 (3.1) 1: p=0.342 
2: p=0.700 
3: p=0.455 
Anxiety 7.5 (4.0) 7.0 (3.9) 7.1 (4.4) 1: p=0.416 
2: p=0.390 
3: p=0.949 
1=Baseline vs after 3 months, 2= Baseline vs after 6 months, 3= After 3 months vs after 6 months 





















Figure 15: HADS sum score for the participants in the eHealth program (I), at baseline, and 3- and 6 
months after the start of the program. Values are reported as mean (SD). 
 
3.2.3.4 RAND-36 
The second questionnaire used to assess whether the patients would experience an improved 
health-related quality of life (HRQOL), during the eHealth program, was RAND-36. This was 
evaluated by comparing the scores at baseline and 3- and 6 months after the start-up of the 
program. Table 12 shows a numerically higher score at 3 months compared to baseline at the 
six categories; general health, pain, energy/fatigue, role limitation due to emotional problems, 
physical functioning and social functioning, but none of these differences were statistically 
significant. The seven categories; general health, pain, emotional well-being, health change, 
role limitation due to emotional problems, physical functioning and social functioning, had a 
numerically higher score after 6 months compared to baseline, but only “pain” was 
significantly different (p=0.008). None of the scores between 3 and 6 months, were 
significantly different. The category energy/fatigue ended up with a numerically lower 









Table 12: The nine RAND-36 categories for the participants in the eHealth program (I), at baseline 
and after 3- and 6 months. Values are reported as mean (SD) / median (IQR), as appropriate. 
 Baseline, mean 
(SD) / median 
(IQR) 
After 3 months, 
mean (SD) / 
median (IQR) 
After 6 months, 
mean (SD) / 
median (IQR) 
p-values 


















72.0 (60.0-80.0) 68.0 (60.0-84.0) 80.0 (60.0-88.0) 1: p=0.159 
2: p=0.060 
3: p=0.565 
Health change 50.0 (50.0-75.0) 
 




due to emotional 
problems 
66.7 (33.3-100.0) 100.0 (33.3-
100.0) 




due to physical 
health 





80.0 (75.0-95.0) 90.0 (75.0-95.0) 90.0 (70.0-95.0) 1: p=0.310 
2: p=0.199 
3: p=0.516 




1 = Baseline vs after 3 months, 2 = Baseline vs after 6 months, 3 = After 3 months vs after 6 months 
P-values are based on paired-Samples T test or repeated measures one-way ANOVA with mean (SD) 
(social functioning, general health) or Wilcoxon matched-pairs signed rank test with median (SD) 
(pain, energy/fatigue, emotional well-being, health change, role limitation due to emotional problems, 





3.2.3.5 HBNKFM0,3,6; Low FODMAP diet 
Table 13, 14 and 15 show the various questions regarding the low FODMAP diet, at baseline, 
and after 3- and 6 months. At baseline, 21 (75%) of the participants had followed a low 
FODMAP diet earlier, and 14 (50%) were still following the diet (Table 13). 3 months after 
the start of the eHealth program, 21 (75%) answered that they had tried the FODMAP diet 
after guidance in the program, whereas 18 (86%) of these patients still followed the diet at 
that time point. 6 months after the start-up, 22 (79%) answered that they had tried the 
FODMAP diet after the guidance in the program, whereas 15 (68%) of these patients still 
followed the diet at that time point. Table 14 and 15 shows a greater spread in the degree of 
experienced symptom relief of the diet, compared to Table 13. 
 
Table 13: Questions regarding the low FODMAP diet from HBNKFM0, at baseline. 
Baseline (n=28)  
Have you followed the low FODMAP diet earlier? Yes/no n (%) 21(75%) / 7(25%) 
1) Do you follow the low FODMAP diet at the moment? Yes/no n (%) 
1A) if yes, how long have you followed the diet? (mean, n=14) 
 
1B) If yes, to what extent have you experienced a symptom relief of the 
diet? (mean, n=14) 
14(50%) / 14(50%) 
16.3 months 
 
Not at all (n=0) 
Slightly (n=3, 21.4%) 
Moderately (n=1, 7.1%) 
Quite a bit (n=6, 42.9%) 















Table 14: Questions regarding the low FODMAP diet from HBNKFM3, after 3 months. 
After 3 months (n=28)  
Have you followed the low FODMAP diet after you got guidance 
in the eHealth program? Yes/no (%) 
 
1A) if yes, have you reintroduced the FODMAP groups (mean, 
n=21)? Yes/no n (%) 
 
1B) Do you still follow a low FODMAP diet (mean, n=21)? Yes/no n 
(%) 
 
1C) To what extent have you experienced a symptom relief of the diet 
(mean, n=21)? 
 
21 (75%) / 7(25%) 
 
13 (62%) / 8 (38%) 
 
18 (86%) / 3 (14%) 
 
Not at all (n=1) 4.8% 
Slightly (n=3) 14.3% 
Moderately (n=4) 19.0% 
Quite a bit (n=7) 33.3% 
A great deal (n=6) 28.6% 
 
Table 15: Questions regarding the low FODMAP diet from HBNKFM6, after 6 months. 
After 6 months (n=28)  
Have you followed the low FODMAP diet after you got guidance 
in the eHealth program? Yes/no (%) 
1A) if yes, have you reintroduced the FODMAP groups (mean, 
n=22)? Yes/no n (%) 
1B) Do you still follow a low FODMAP diet (mean, n=22)? Yes/no n 
(%) 




22 (79%) / 6 (21%) 
 
16 (73%) / 6 (27%) 
15 (68%) / 7 (32%) 
 
Not at all (n=2) 9.1% 
Slightly (n=3) 13.6% 
Moderately (n=2) 9.1% 
Quite a bit (n=10) 45.5% 
A great deal (n=5) 22.7% 
 
 
3.2.3.6 Correlation analysis 
Correlation analysis were performed between IBS-SSS sum score and IBS-QOL overall 
score, at baseline, and 3- and 6 months after the start of the eHealth program (I). The number 
of patients was reduced to 25, due to some missing data, and to have equal sample, same as 





The correlation analysis showed a statistically significant negative correlation between IBS-
SSS sum score and IBS-QOL overall score, at baseline (r= -0.483, r2=0.233, p=0.015), at 3 
months after the start-up (r= -0.469, r2=0.220, p=0.018), and after 6 months (r= -0.701, r2 = 
0.491, p=0.0001). It also showed that at baseline, at 3 months and at 6 months, the proportion 
of the variation in IBS-QOL explained by the variation in IBS-SSS sum score was 23.3%, 
22.0% and 49.1%, respectively. This shows that a high severity of IBS-like symptoms is 
correlated with reduced quality of life, which suggests that an improvement in IBS-like 



















Figure 17: Pearson correlation showed a significant and negative correlation between IBS-SSS sum 






3.2.4 Comparison of the results from the eHealth program (I) with control group 1 
 
3.2.4.1 IBS-QOL 
We were interested in comparing the IBS-QOL mean difference, between baseline and after 3 
months, of the eHealth program (I) and control group 1. The latter control group consisted of 
three regular, physical IBS-schools at LMS in April, May and June 2017. Table 16 and 17 
shows that the score from control group 1 numerically increased from baseline to after 3 
months, with a mean difference of -3.9, but it was not statistically significant (p=0.485). On 
the other hand, the score from the eHealth program (I) increased significantly between the 
same to time points, with a mean difference of 9.2 (p=0.001) (Table 17). 
 
 
Table 16: IBS-QOL overall score (0-100) for the participants in control group 1, at baseline and 3 
months after the school. Values are reported as mean (SD). 
 Baseline, mean (SD) 
(n=20) 





39.2 (17.8) 43.1 (27.3) 1: p=0.485 
P-value is based on paired-Samples T test with mean (SD) 
 
Table 17: IBS-QOL overall (0-100) differences between baseline and after 3 months, in the eHealth 
program (I) and control group 1. Differences are given as mean (95% CI). 
Symptoms  eHealth program (I): 
Baseline versus after 3 months 
(n=30) 
 
Control group 1; regular IBS-
school at LMS 










IBS-QOL overall score 9.2 (4.2, 14.1) 0.001** 3.9 (-7.5, 15.3) 0.485 
P-values are based on paired-Samples T test  






We were also interested in comparing the IBS-SSS mean difference, between baseline and 
after 3 months, of the eHealth program (I) and control group 1. The latter control group 
consisted of three regular, physical IBS-schools at LMS in April, May and June 2017. Table 
18 and 19 shows that the score from control group 1 numerically decreased from baseline to 
after 3 months, with a mean difference of 7.0, but it was not statistically significant (p=0.617). 
On the other hand, the score from the eHealth program (I) decreased significantly between the 
same to time points, with a mean difference of 64.4 (p=0.00004) (Table 19). 
 
Table 18: IBS-SSS sum score (0-500) for the participants in control group 1, at baseline and after 3 
months. Values are reported as mean (SD). 
Symptoms Baseline, mean (SD) 
(n=20) 
After 3 months, mean 
(SD) (n=20) 
p-value 
IBS-SSS sum score 286.8 (62.5) 279.8 (78.5) 0.617 
P-values is based on paired-Samples T test 
 
Table 19: IBS-SSS sum score (0-500) differences between baseline and after 3 months, in the 
eHealth program (I) and control group 1. Differences are given as mean (95% CI). 
Symptoms  eHealth program (I): 
Baseline versus after 3 months 
(n=26) 
 
Control group 1; regular IBS-
school at LMS 










IBS-SSS sum score 64.4 (37.6, 91.3) 0.00004**** 7.0 (-21.8, 35.8) 0.617 
P-values are based on paired-Samples T test  









3.2.5 Comparison of the results from the eHealth program (I) with control group 2                                                      
 
3.2.5.1 IBS-SSS 
We were interested in comparing the IBS-SSS mean difference, between baseline and after 6 
months, of the eHealth program (I) and control group 2. The latter control group consisted of 
IBS-patients, participating in a two-days, extended, physical IBS-school at LMS in October 
2015. Table 20 and 21 shows that the score from control group 2 numerically decreased from 
baseline to after 6 months, with a mean difference of 32.3, but it was not statistically 
significant (p=0.094). On the other hand, the score from the eHealth program (I) decreased 
significantly between the same to time points, with a mean difference of 78.7 (p=0.001) 
(Table 21). The comparison of the development in eHealth program (I) and control group 2 is 
illustrated in Figure 16. 
 
 
Table 20: IBS-SSS sum score (0-500) for the participants in control group 2, at baseline and after 6 
months. Values are reported as mean (SD). 
Symptoms Baseline, mean (SD) 
(n=71) 
After 6 months, mean 
(SD) (n=32) 
p-values 
IBS-SSS sum score 298.0 (83.0) 265.7 (103.3) p=0.094 
P-value is based on summary independent-Samples T test 
 
 
Table 21: IBS-SSS sum score (0-500) differences between baseline and after 6 months, in the 
eHealth program (I) and control group 2. Differences are given as mean (95% CI).  
Symptoms  eHealth program (I): 
Baseline versus after 6 months 
 
 
Control group 2; extended IBS-
school at LMS  










IBS-SSS sum score 78.7 (37.4, 120.0) p=0.001** 32.3 (-5.6, 70.2) p=0.094 
P-values is based on paired-Samples T test (eHealth program (I)), and summary independent-























eHealth program (I) vs control group 2









Figure 16: Comparison of the development of the mean IBS-SSS sum score from baseline to 6 
months after, between the participants at the eHealth program (I) and the participants in the control 
group 2 participating at the extended IBS-school at LMS. Values are reported as mean (SD). 
 
 
3.3 Results from the participants who completed the 3months evaluation, eHealth 
program (II) 
In the second analyze (II) of the eHealth program, the mean and individual responses of the 
40 study participants who completed the eHealth program and responded to the 3 months 
evaluation, were assessed. Some of the participants have not completed all of the 
questionnaires, so n will vary from form to form.  
 
3.3.1 Study population and baseline characteristics of eHealth program (II) 
Baseline characteristics of the 40 patients that completed the 3 months evaluation (eHealth 










Table 22: Baseline demographic of the 52 patients included in the study, compared to the 40 that 
completed the eHealth program and 3 months evaluation (II). 
PARTICIPANTS Total included 









Female/male 36/16 26/14  
Mean age (range), years 37.6 (15-66) 37.1 (15-56)  
Severity of symptoms 














n = 5 (10%) 
n = 23 (44%) 







n = 3 (7.5%) 
n = 18 (45%) 
















1 = Total included in the study vs eHealth program (II) 
P-value is based on summary independent-Samples T test with mean difference (SD) 
 
3.3.1.1 Gender and age  
Among the 52 included participants in the study, 36 were female (69%). Of the 40 patients 
who completed the 3 months evaluation and are hence a part of the eHealth program (II), 26 
were female (65%). The mean age among the 52 included was 37.6 years (range, 15-66 y), 
and among the 40 in the eHealth program (II) it was 37.1 (15-56). 
 
3.3.1.2 IBS severity 
Table 22 shows baseline mean IBS-SSS sum score for the 52 study participants included in 
the study, as well as for the analyze of those who completed the 3 months evaluation; eHealth 





was 293.1 (range, 149-500) for the eHealth program (II), but the difference wasn’t statistically 
significant (p=0.837). The distribution of the IBS severity was for the 52; mild=5 (10%), 
moderate=23 (44%), severe=24 (46%) and for the eHealth program (II); mild=3 (7.5%), 
moderate=18 (45%), severe=19 (47.5%). 
 
3.3.1.3 IBS-QOL 
The baseline mean IBS-QOL overall score for the 52 study participants included in the study, 
and for those who completed the eHealth program (II) were 45.8 and 48.4, respectively (Table 
22). The difference was not statistically significant (p=0.490). 
 
3.3.2 Changes during the eHealth program (II): differences between baseline and 3 months 
 
3.3.2.1 CSQ-8 
Table 23 shows the mean (SD) scores of the eight questions from the Client Satisfaction 
Questionnaire (CSQ-8), as well as the mean of item means and mean total score, for both the 
participants in the eHealth program (II) and control group 1, as a part of the 3 months 
evaluation. For the eHealth program, most of the questions lie on a mean score around 3, with 
a mean of item means at 2.98, which shows a generally good satisfaction with the program. 
Of the 8 questions “the quality of the service” (Q1) was rated the lowest mean score (2.69), 
and “recommendation to a friend” Q4 with the highest (3.36). Mean total score for the 
eHealth program was 23.86, compared to control group 1, which had a mean total score of 












Table 23: 8 Client satisfaction questions (73), Q1-Q8 (1-4) and mean total score (8-32) for the 




1; physical IBS 
school at LMS 
p-value 
 degree of 
satisfaction from 
1-4  








Q1: How would you rate the quality of 
service you have received? 
2.69 (0.67) 2.95 (0.76)  
Q2: Did you get the kind of service 
you wanted? 
2.89 (0.52) 3.15 (0.59)  
Q3: To what extent has our program 
met your needs? 
2.78 (0.76) 2.75 (0.91)  
Q4: If a friend were in need of similar 
help, would you recommend our 
program to him or her? 
3.36 (0.64) 3.65 (0.49)  
Q5: How satisfied are you with the 
amount of help you have received? 
2.92 (0.77) 2.65 (0.75)  
Q6: Have the services you received 
helped you to deal more effectively 
with your problems? 
3.00 (0.68) 3.15 (0.67)  
Q7: In an overall, general sense, how 
satisfied are you with the service you 
have received? 
3.03 (0.74) 3.0 (0.73)  
Q8: If you were to seek help again, 
would you come back to our 
program? 
3.19 (0.82) 3.5 (0.69)  
mean total score (sum of all the 
items)  
23.86 (4.19) 24.8 (4.26) 1: p=0.427 
Mean of item means  2.98 (0.73) 3.1 (0.76)  
 
1 = mean total score eHealth program (II) vs control group 1 









3.3.2.2 HBNKFM3; eHealth program (II) 
Figure 18 illustrates the patients’ degree of satisfaction with the different modules in the 
eHealth program (II). 35 of the study participants who completed the HBKNKFM3 
questionnaire, at the 3 months’ evaluation, answered how satisfied they were with Module 1 
(with gastroenterologist). The same amount gave their feedback on module 2 (with 
physiotherapist) and module 3 (about lifestyle and dietary advice with clinical dietitian). Only 
34 of them evaluated module 4 (with psychiatrist), and only 32 out of the 35, reported their 
satisfaction regarding module 5 (about the low FODMAP diet with clinical dietitian). This 
might be due to the fact that they had only finished the first three and not yet started the last 
two modules, at the 3 months’ evaluation. Based on the pie chart, it may look like the largest 

































Figure 18: Degree of satisfaction of the different modules in the eHealth program (analyze II); module 





















4. DISCUSSION  
There are limited studies on such a web-based treatment for IBS patients, with an 
interdisciplinary approach, that we have implemented and conducted. The interdisciplinary 
approach is based on the fact that IBS is a heterogenous disorder, with the suggestion of being 
a generic term for many diseases with different pathogenesis, but with the same symptoms (4, 
8, 13). Because IBS is a heterogenous disorder that cannot be cured, the treatment has so far 
mainly been recommended to be individualized and be based on the patient's predominant 
symptoms (8, 14, 17, 25). Due to the fact that the treatment options for IBS patients are wide, 
ranging from pharmacological treatment, psychological interventions and guidance on diet, 
lifestyle and physical activity(4, 15, 26), this eHealth program was developed 
interdisciplinary by gastroenterologist, physiotherapist, clinical dieticians and psychiatrist. 
This web-based program covers many of the treatment fields for IBS patients, which might be 
the reason for the successful results of this program. It might also support that IBS is a 
heterogenous group that needs to be treated individually with different approaches, or in a 
combination of the different treatment options.  
 
4.1 Main findings 
The primary aim of this prospective, open, pilot study, was to evaluate whether the eHealth 
program could be effective as a healthcare measure. This was assessed, based on the effect of 
the program itself, but also in comparison with the effect of the current program; the physical 
IBS-school at LMS. 52 participants were included in the study. 40 of these patients completed 
the 3 months evaluation and their data were the basis of the analysis of the eHealth program 
(II), whereas 31 completed the 6 months evaluation and were the basis of the analysis of the 
eHealth program (I).  
 
In the analysis of eHealth program (I), mean IBS-SSS sum score and 4 out 5 IBS symptoms, 
significantly improved from baseline to after 3 months. Improvements were also seen from 
baseline to after 6 months, where mean IBS-SSS sum score and 3 out of 5 IBS symptoms 
significantly decreased. Individually, 20 (76.9%) of the 26 participants either improved their 
IBS-SSS sum score significantly from baseline to after 3- or 6 months, and the distribution of 





Enhancement in the participants quality of life was assessed according to IBS-QOL from 
baseline to after 3 months, where mean IBS-QOL overall score and 5 out of 8 IBS-QOL 
subscale scores significantly increased. From baseline to after 6 months, the mean IBS-QOL 
overall score and 7 out of 8 IBS-QOL subscale scores significantly improved. The only 
subcategory in the RAND-36 questionnaire that showed a significant improvement, was 
“pain”. The rest of the categories did not alter significantly, neither from baseline to after 3 
nor 6 months. The HADS sum score and the subscale scores anxiety and depression 
numerically decreased from baseline to after 3- and 6 months, but neither of the 
improvements were statistically significant. The correlation analysis between IBS-SSS sum 
score and IBS-QOL overall score, at baseline, and after 3- and 6 months, showed that all of 
them were statistically significant negative correlated. The ROME III criteria questionnaire 
contained a lot of "insufficient information", which made the utilization of the data difficult. 
In control group 1, mean overall IBS symptoms and mean IBS-QOL overall, numerically 
improved from baseline to after 3 months, but it was not statistically significant. In control 
group 2, the overall IBS symptom scores numerically decreased from baseline to after 6 
months, but neither were statistically significant. 
 
In the analysis of the 40 participants who completed the 3 months evaluation (eHealth 
program (II)), showed a generally good satisfaction with the program, based on CSQ-8. 
According to HBNKFM3, it looked like the largest proportion of the participants were most 
satisfied with module 5 (low FODMAP diet with clinical dietitian), and least satisfied with 
module 4 (with psychiatrist). 
 
4.2 Discussion of main findings 
 
4.2.1 Study group and sample size 
Due to the drop-out throughout the study we found it important to evaluate whether the 52 
participants included differentiated from the groups who completed 3 and/or 6 months 
evaluations. Gender distribution and mean age, at baseline, in the eHealth program (I) and (II) 
are quite similar to the 52 originally included, differentiating with a slight increase in the 





a small reduction from the mean baseline IBS-SSS sum score of the 52 (296.8) till the eHealth 
program (II) (293.1) and a slightly larger reduction from the 52 till the eHealth program (I) 
(282.5), but neither of them were statistically significant. The proportion of the different 
categories of baseline severity didn't differentiate so much between the three groups. The 
baseline demographics of the mean IBS-QOL overall score, for the 52 included in the study, 
and for the participants in the eHealth program (II) and (I) was 45.8, 48.4 and 50.0, 
respectively. Neither of these slight increases from the 52 included in the study, were 
statistically significant.  This indicates that the analysis of the participants in the eHealth 
program (II) and (I) may represents the 52 originally included in the study, which again might 
be representable for the IBS population who seek specialist healthcare services. 
  
Interestingly, the dropouts had a higher mean IBS-SSS sum score and a lower IBS-QOL 
overall score. In terms of age, the dropouts were among the oldest and youngest participants. 
From the 52 included in the study and up to 3 months (eHealth program (II)), it was the age 
range between 57-66 who dropped out. Similarly, from the 52 included in the study up to 6 
months (eHealth program (I)), it was the age range between 15-19 and between 57-66 who 
dropped out. This indicates that the eHealth program might be best suited for the age range 
around 20-60 years. We did not initially include participants under the age of 18 years (except 
one), since the educational program does not have a pediatric design. There are obviously 
individual differences, but our results demonstrated that the initially set age-range was 
appropriate. It is therefore possible to suggest that the eHealth program is more suitable for 
participants aged 20-60 years. The eHealth program may not be suitable for younger 
participants, and older may find it too technically challenging. 
  
4.2.2 The questionnaires responded by the participants in the eHealth program (I) 
 
4.2.2.1 IBS-SSS and IBS-QOL 
There were significant improvements in mean IBS-SSS sum score and a large proportion of 
IBS symptoms, from baseline to both 3- and 6 months after the start of the program, in the 
participants who completed the 6 months evaluation (eHealth program (I)). There were also 





subscale scores, between the same time points, for the participants who completed the eHealth 
program (I). There is limited research on the same type of interdisciplinary web-based 
treatment for IBS patients, like the one we have conducted. However, some similar studies 
regarding internet-based treatments for IBS patients both support and contradict our results, as 
e.g. one internet-based self-management program showed no significant improvement in 
quality of life (53), while two internet-based cognitive behavior therapy studies showed 
significant improvement on IBS symptoms and quality of life (54, 55). A study by joc et al 
(52) used another educational platform; an outpatient clinic in addition to written information, 
but included much of the same content as in the eHealth program. They concluded that the 
IBS patients had significantly improved their quality of life and significantly reduced their 
IBS-related complaints (52). 
 
The correlation analysis between IBS-SSS sum score and IBS-QOL overall score, at baseline, 
and after 3- and 6 months, showed that all of them were statistically significant negative 
correlated. That indicates that the severity of IBS symptoms is correlated with reduced quality 
of life. These findings are supported by Mönnikes (9) and De Gucht (76), which conclude that 
the severity of IBS symptoms directly correspond to the effect on total HRQOL. And patients 
who experience worse IBS symptoms, have a more reduced quality of life, than those with 
milder sufferings (9). De Gucht (76) also conclude that the patient’s perception and coping of 
the disease, have an indirect impact on their HRQOL. One of the primary intentions with the 
eHealth program is to help the patients to cope with the disease better, and as the results 
showed significantly improved IBS symptoms and quality of life, this might successfully have 
been one of the reasons. 
 
4.2.2.2 Comparison of the eHealth program (I) with control group 1 and 2 
The differences in mean IBS-SSS sum score and mean IBS-QOL overall score, between 
baseline and after 3 months in control group 1, improved numerically less than in the eHealth 
program (I), between the same scores and time point (as shown in Table 17 and 19). The same 
was assessed in control group 2, which had a numerically lower mean difference in IBS-SSS 
sum score, between baseline and 6 months, than the eHealth program (I), at the same scores 





were statistically significant, which makes the comparisons difficult. Anyway, this indicates a 
trend toward the conclusion that the eHealth program is not less effective than the IBS-school 
at LMS. This is somewhat contradictory to, for example, a previous RCT study that concluded 
that in the treatment of IBS, "structured patient group education (IBS school)" is a better 
alternative than written information (58). However, this is not completely comparable to the 
eHealth program as it contains more than just written information.  
 
4.3 Limitation of the study 
 
4.3.1 study group and sample size 
One major weakness of the study is the high dropout rate. This is something we feared, when 
increasing the risk of it, by choosing a duration of the study period as long as 6 months. Even 
though age and gender were quite similar in the eHealth program (I) and (II) as the 52 
included participants, and there were no statistically significant differences between mean 
IBS-SSS sum scores between those mentioned, there will still be an uncertainty on whether 
the dropouts may have affected the other results, and possibly in both directions.  
A possible weakness of the study is that we have not controlled, whether the patients have 
participated in other treatment options, during the study period. Two of the participants 
reported less symptoms after surgery during the study period, and one reported the same 
incident due to pregnancy, which we therefore excluded, to avoid falsified positive results. 
However, we did not control for this or other similar cases (like pregnancy) systematically, 
within the other participants. We have also not controlled whether the patients suffer from 
other comorbidities. This might be a limitation with the study, but it’s also important to 
remember that IBS is a heterogenous group (8), and we wanted the study population to be as 
representative for the IBS population as possible. This is also due to the long-term goal of 
implementing the eHealth program nationally, as a low-threshold offer, for all patients with 
IBS, regardless of this. At the same time, it’s worth mentioning that this is neither controlled 
for in control group 1 nor 2, which might have affected all of the groups in the same way, 







4.3.2 Control groups and samples sizes 
Due to ethical considerations, the written consent form that the participants received at the 
IBS school at LMS had to be signed before completing the questionnaires. This resulted in 
most of the participants responding to the different questionnaires after the first day of the 
course. Ideally, they should have replied to the questionnaires before they started the course, 
which makes this a weakness, as they already might have had a positive effect when they 
completed the questionnaires. The implementation of a separate electronic platform for 
control group 1 was dependent on Helse Bergen-Section for eHealth. The 6-month delay of 
this, which had nothing to do with the master student, meant that this was not started before 
April. This resulted in a low number of patients in this control group (n = 20), which makes 
the control group 1 weak. Another weakness with the control groups is that the IBS school at 
LMS is not a validated gold standard (yet), but only developed based on the participants’ 
satisfaction and feedback. 
 
4.3.3 Evaluation of the placebo effect 
Since our study is not a randomized, blinded, placebo-controlled trial, the placebo effect will 
be essential to evaluate here. This familiar phenomenon has often been demonstrated in 
clinical research (77). It has been assessed that participants in studies receiving the placebo 
product have nevertheless experienced unexplained symptom relief (77). The quality of the 
relationship between the patient and the therapist, the subject’s belief in the 
product/intervention as well as their expectations, are among other possible factors that might 
be associated with the placebo effect (78). The fact that the participants in the eHealth 
program were involved in such treatment, where they might have felt that they were taken 
seriously and finally got some tools that could help them, can itself have provided an 
expectation of an effect. This might have resulted in a placebo effect and positively affected 
the results. The fact that the patients know that they are participating in a guided intervention 
by experts in their respective fields (gastroenterologist, physiotherapist, clinical dietitian, 
psychiatrist) might also have amplified the expectation of an effect. Despite few meetings 
during the study period, participants may have felt a certain interaction with the people 
affiliated with the project, which in turn may have contributed to a potential placebo effect. 





the potential placebo effect. For the same reason, we also chose to compare the results of the 
eHealth program with two control groups. The participants in these control groups had 
physically attended to the IBS-school at LMS, where the expectation of an effect is also 
present. As discussed by Miller (77) the possible placebo effect in IBS trials, can be reduced 
by having a study duration longer than 12 weeks as well as lowering the frequency of follow-
up meetings. This might again enhance the statistical power (77). Our study lasted for a total 
of 6 months, and had few meetings along the way (only 2 voluntary meetings regarding 
information- and evaluation), which might have reduced some of the placebo effect in the 
study. 
 
4.3.4 The questionnaires 
First of all, one limitation with the study is that all of the data are based on the self-reported 
data from the questionnaires. Another limitation about the questionnaire is that two of the 
questionnaires (IBS-SSS and ROMEIII), were completed by participants in two different 
ways, on paper at baseline and after 3 months, and electronically after 6 months, due to 
license delay. Although the intention was that the electronic questionnaires would match the 
printed editions as well as possible, there would still be two different formats, which gave the 
possible rise to different interpretations of the questionnaires and bias that couldn’t be 
adjusted for. 
  
Another aspect is that some of the participants reported that it was time consuming to fill out 
all of the questionnaires (6 + CSQ-8), at three different times (baseline, after 3 months, after 6 
months), and in addition split it up in two different ways (by post and electronically). If all the 
questionnaires had been electronic all the way, it would also have been much more convenient 
for us to get a systematic overview, along the way, over respondents of the various 
questionnaires. It would therefore have been much easier for both the project workers and also 
the participants, if all of the questionnaires had been electronically. This might also have 









A weakness with the IBS-SSS questionnaire (see appendix 9) is that if one of the subscale 
scores questions remains unanswered, the participant will still get a total score. For example, 
if a participant answer "no" that they do not suffer from abdominal pain at the moment (1a) 
then it is natural that they will let (1b), which ask for the severity of abdominal pain, be 
unanswered. This will then most likely give the correct outcome on total score, but give less 
number (n) to the actual subscale score (1b); "severity of abdominal pain", as we have no 
value of the patient. One possibility is to override writing "0" on these examples but then 
one's own interpretation of the form will become subjective, which is why the master's student 
has chosen not to do so. In addition, some participants have answered "no" on (1a) and yet 
scored a low score of (1b), which makes it clear that patients may interpret the questionnaire 
differently, and override will not be the right solution. Oppositely some patients have 
answered yes on (1a) and left (1b) unanswered.  
 
Subsequently, most of the time, it may be “right” with lower (n) on the subscale score than the 
sum score, due to patients suffering from different IBS like symptoms. Some patients might 
for example not suffer from abdominal distention (no responded value on this subscale, but 
still get a value on the sum score), but from abdominal pain. This will therefore not affect the 
sum score, but other times will different interpretations might lead to missing data that affects 
the total sum. This can therefore result in an incorrectly reduced total sum score. However, 
this applies for the questionnaire in both forms (and therefore in all questionnaires sent out at 
the different time points, at baseline and after 3- and 6 months), and might therefore equalize 
the bias. Since this master thesis has contained 431 variables per participant, there has been no 
capacity to go through each variable and optionally remove any patient due to 
errors/weaknesses with the implementation of this standardized questionnaire. The master 
student has therefore dealt with the sum score values that have come from the raw data of the 
participants, but noted this weakness with the questionnaire. However, this is corrected for the 
subscale scores, resulting in smaller number (n) of participants, so that all variables have been 







4.3.4.2 Rome III criteria 
One of the inclusion criteria was that the patients had gotten the IBS-diagnosis from either 
their general practitioner (D93) or by a specialist in gastroenterology (K58). Given the idea 
that the eHealth program should be a low-threshold healthcare service, we did not set Rome 
III criteria as an additional inclusion criterion. However, we were still interested to see if the 
patients would get the IBS-diagnosis based on the Rome III criteria by filling out this 
questionnaire. Unfortunately, this form caused some confusion due to the format layout, 
which resulted in some missing data. Many participants misinterpreted that the questions 44-
50 are sub-questions to question 43, because they are indented below this question. This has 
resulted in some male participants believing that question 44-50 are intentionally for women, 
as well as question 43, and let all of these questions be uncompleted (they wrote on the side “I 
am a man” and skipped these questions). It also looked like some female participants have 
uncompleted questions 44-50, when they have completed “no” on question 43, and thought 
they were dependent of each other. Altogether, it gave us a lot of "insufficient information to 
provide an IBS diagnosis", hence not useful to use the questionnaire. Some 
gastroenterologists believe that not everyone suffering from irritable bowel syndrome will 
fulfill the ROME III criteria for IBS, and that you should not trust these criteria blindly. Even 
though the ROME III criteria are presently the most accepted tool, at standardizing the IBS-
diagnosis(77), there are arguments that these criteria are not validated enough and that they 
are seldom utilized in clinical practice(79), and also that they only have a moderately ability 
to classify all of the IBS patients accurately(80). 
 
4.3.4.3 HBNKFM 0,3,6 low FODMAP diet 
It is important to emphasize that the HBNKFM questionnaires are not validated, and thus only 
used and interpreted as satisfaction and feedback from the participants. Of the 14 patients who 
responded that they followed a low FODMAP diet at baseline, a percentage between 78.6 % 
(answered either moderately, quite a bit or a great deal) and 100% (answered either slightly, 
moderately, quite a bit or a great deal), answered that they had experienced a symptom relief 
of the diet in some degree. This is supported by earlier studies, where e.g. Nanayakkara et al 
(46), suggested that as much as 86% of the patients suffering from IBS experience an 





with the questionnaire is that it only asks the participants who still follow the diet, about their 
experience with symptom relief. It’s reasonable to believe that the patients who still followed 
the diet at baseline, are the ones that do have experienced a symptom relief of the diet. When 
we made the questions, it would possibly have been better to ask all the participants who had 
tried the diet, on what kind of experience they had made, regarding symptom relief. This is a 
great limitation, when interpreting the rest of the answers.   
 
6 patients answered that they experienced a symptom relief a great deal, after attending the 
eHealth program for 3 months, and only 5 answered the same after 6 months. A possible 
reason might have been an unsuccessful reintroduction of the FODMAPs. The percentage of 
the participants who had followed the diet after guidance in the eHealth program and 
reintroduced the FODMAPs, were 62% after 3 months and 73% after 6 months. This might 
support that a long-term follow-up, with dietary guidance by a clinical dietitian, like e.g. 
Nanayakkara et al (46) have suggested, might play a major role in the potential effect of the 
diet.  
 
4.4 Possible improvements 
 
4.4.1 The questionnaires 
The problem with the IBS-SSS questionnaire might be avoided by being created in a way that 
forces the patient to complete all the questions before proceeding, and if he/she hasn't 
completed all the necessary questions, the participant shouldn't get a total score. Generally, in 
the results, the number of completed (n) varies from questionnaire to questionnaire, so the 
same applies to the rest of the forms. In this way, it will not be possible for the participant to 
skip any of the individual questions or questionnaires. 
A suggestion for improvement could also be removing question 1a and 2a on IBS-SSS, which 
might make every participant answering 1b and 2b. Since some of the sub-questions on IBS-
SSS require the participants to "drag" an arrow on the VAS score that describes them best, 
instead of putting a cross at a line on a sheet, like the paper edition, there is always a chance 





wise to make a little explanation box on the page, and to spend even more time trying to make 
generally everything in the eHealth program as simple as possible to use.  
 
4.4.2 The eHealth program 
Unlike the physical IBS school at LMS, the patients who participate in the eHealth program 
do not meet other people in the same situation whom they can exchange advices and 
experiences with. A suggestion for possible improvement can the signing up for an organized 
meeting, where participants have the opportunity to meet others, and thereby feel less alone in 
their situation.  
 
Furthermore, the program should be improved in the sense that it is easier to monitor patient 
use of the program. Based on the present development of the program, we didn’t have this 
opportunity, which made it impossible for us to differentiate between which of the patients 
who had utilized the program in a great extent from those who hadn’t. Another aspect of 
further development of the eHealth program is user perspective and user involvement, 
whereas patient feedback is important for possible improvements with the program.  
 
4.4 Further research 
There is a need for more patients to test the eHealth program, in order to be more certain 
about the effect of the program. There is also a need for better control groups, with larger (n) 
in both the study population and the control group. To investigate the effect of this program 
further, future research could contain a RCT study. This could e.g. investigate the effect of the 
eHealth program compared to the effect of other validated treatment options. This will 
strengthen the results, as well as give more insight to whether the results could have been 
caused by chance. Furthermore, in the recruitment of more participants, a suggestion can be to 
screen and evaluate which patients are motivated for this kind of program. It requires self-
discipline and that they set aside time for it, and not all the patients are motivated for that. All 
the potential participants we tried to recruit to the eHealth program, wanted to participate. We 
should have put more emphasis on what it was going to require of the participants, to avoid 





how motivated the patient are, and who would rather be better suited on e.g. a two-day 
physical IBS school.  
 
The long-term goal of this pilot study and a further expansion of the study, have along the 
way, been to implement the eHealth program nationally as a primary healthcare offer through 
the general practitioner system, requiring that enough participants have showed an effect of 
the program. The underlying objective of this, is to reduce the waiting line for patient 
education for functional gastrointestinal diseases by giving them quick access to the eHealth 
program. This will give them help with self-help, based on "knowledge is empowerment". 
This could also be a tool for general practitioners (GP), and also resulting in better 
distribution of the work between the primary and specialist health care.  
 
If the eHealth program becomes implemented nationally as a healthcare measure, the eHealth 
program could in the future, be used to create a quality register for functional gastrointestinal 
disorders. This could provide information on the patient's experience of different treatment 
options, as well as data of e.g. the patients' symptoms and severity, drug use and so on. 
Examples of future studies, could be comparison of the development of the use of the eHealth 
program and drug use, or comparison of development of IBS symptoms and quality of life, vs 
use of the eHealth program. 
 
Another aspect with this program is the cost-effectiveness. Since the worldwide prevalence of 
IBS is as much as around 11.2% (11), and it contributes to major healthcare costs, both 
directly by patient care and indirectly by absenteeism at work (4, 5, 7, 8), it’s important to 
have an available treatment option, which doesn’t contribute to major health care costs. As 
discussed by Mishima et al (81), it’s important that the patients are well educated about their 
disease, which will help them cope with it better, and hopefully reduce their symptoms 
without unnecessary cost expenditures and without adverse side effects. An earlier study on 
ICBT conducted by Ljótsson et al concluded that it could be a cost-effective treatment option 
(55). The eHealth program can be a cost-effective treatment option for IBS patients in the 
future, by being a cheap, easily accessible to patients independently of geographic location, 





 5. CONCLUSION 
 
• IBS symptoms significantly improved from baseline to both 3- and 6 months after the start 
of the eHealth program. 
• Health-related quality of life significantly improved from baseline to both 3- and 6 months 
after the start-up. 
• IBS symptoms were significantly and negatively correlated with quality of life, at baseline 
and after 3- and 6 months. This supports previous data that the severity of IBS symptoms 
directly corresponds to the effect on total HRQOL.  
• The mean improvement in IBS symptoms and IBS-QOL scores were lower in both control 
groups, compared to the eHealth program, but none of the changes in the control groups 
were statistically significant. However, this suggests that the eHealth program is not less 
effective than the current program; the IBS-school at LMS. 
• Results from the Client Satisfaction Questionnaire showed a generally good satisfaction 
with the program. 
 
Altogether, the positive results from our pilot study, support the conclusion that the eHealth 
program can be effective as a healthcare measure. There is a need for more patients to test the 
eHealth program, in order to be more certain about the effects and duration of the effects of 
the program. Based on our results, it supports that it’s worth further investment in the project, 
so that the eHealth program may become a nationally cost-effective treatment option for IBS 
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Appendix 1: Research Protocol 
 
 
Kommentar til forskningsprotokoll: For Mage-tarmskolens innhold se eget vedlegg (160 
sider). Magetarmskolen består av 5 moduler hvor modul 1,2 og 4 er pasientopplæring og 
modul 3 og 5 er kostholdsintervensjon. Forskningsprotokoll for kostholdsbehandling er 









Forskningsprotokoll   
Kostbehandling ved irritabel tarm – Magetarm-skolen på nett  
Bakgrunn  Flere mennesker med IBS rapporterer at spesifikke matvarer 
induserer og/eller forverrer deres symptomer. Typiske  
”problemassosierte matvarer” omfatter fet mat, stekt mat, sterkt 
krydret mat, røkt og sterkt saltet mat, hvete/gluten, mye 
kostfiber, alkohol, koffeinholdig drikke (kaffe, te, cola, 
energidrikker) og matvarer med høyt innhold av 
tungtfordøyelige karbohydrater (FODMAPs). En lav 
FODMAP-diett er den eneste vitenskapelig beviste 
kostholdsterapien for lindring av IBS-symptomer, og blir i 
økende grad valgt som førstebehandling (1,2,3).  
Tungtfordøyelige karbohydrater blir ikke absorbert tilstrekkelig 
i tynntarmen, og vil være osmotisk aktive og fermenteres, noe 
som kan resultere i luftplager, smerte og forstyrret  
avføringsmønster. Kostbehandling ved IBS har det overordnede 
mål om et mest mulig variert kosthold med minst mulig 
symptomer. Dette innebærer å ikke kutte ut alt som mistenkes å 
gi problemer, men heller det man gjentatte ganger har erfart gir 
problemer. Ved å først redusere FODMAPs i kosten, for så å 
systematisk reintrodusere FODMAP-gruppene, vil man 
redusere risikoen for et utilstrekkelig inntak av viktige 
næringsstoffer og dermed sikre et fullverdig kosthold (4).  
  
Mål   Identifisere om tverrfaglig veiledet selvhjelp sammen med 
veiledet lavFODMAP-kostholdsintervensjon leder til endringer 
i pasientrapporterte symptomer og livskvalitet hos pasienter 
med irritabel tarm.  
  
Studiedesign og metode  
  
Denne studien er en prospektiv, åpen studie. Det skal benyttes 




Etter inklusjon skal pasienten veiledes i lavFODMAP-dietten 
over internett (2-6 uker) av klinisk ernæringsfysiolog.    
  
Inklusjonskriterier   
  
Pasienten må ha diagnosen irritabel tarm,  enten fra fastlegen 
ved ROMA-kriteriene eller som en ekskluderingsdiagnose ved 
spesialisthelsetjenesten. Pasienten skal ikke ha «rød-flagg» 
symptomer som feber, blod i avføringen, eller diare om natten 
(under søvn).  
  
Antall deltagere: 60 (ønskelig 50-50 menn/kvinner)  







   
Datainnsamling   Pasienten skal besvare medisinske spørreskjema a) før oppstart, 
b) 3 måneder etter oppstart, c) 6 måneder etter oppstart.   
  
Følgende spørreskjema skal besvares:  
  
1) Gradering av mageplager (IBS-SSS)  
2) Spørreskjema om mageplager (ROMA III)  
3) Spørsmål om uro og bekymring (EPQ-N-12)  
4) Spørsmål som handler om hvordan du oppfatter helsen 
din  
(RAND-36)  
5) Personlighetstest (NEO-PI-3 og NEO-FFI-3)  
6) Spørsmål om angst og depresjon (HAD)   
7) Spørsmål om livskvalitet i forbindelse med mageplager 
(IBSQOL)   
8) NKFMs spørreskjema om symptomer, hyppighet og 
sykehusbesøk.  
  
Alder   





Database lagres ved sykehusets Forskningsserver. Kun 
prosjektleder har tilgang til nøkkel.   
  
















I modul 3 av mage-tarmskolen, får pasienten opplæring i 
generelle livsstilsråd for irritabel tarm (NICE guidelines) (5), og 
blir oppfordret til å følge disse gjennom hele behandlingen. Det 
blir også gjennomgått kostholdsfaktorer og anbefalinger for 
fiberinntak og magetarm-problemer.   
  
  
1 dag  
  
  





Fase 2 (Modul 5)  
  
FODMAP- 





Dersom pasienten ikke opplever tilfredsstillende 
symptomlindring etter de tidligere modulene, skal de gå videre 
til modul 5 og prøve FODMAP-redusert kosthold. 
FODMAPredusert kosthold skal følges i 2-6 uker, avhengig av 
grad av symptomlette.  
Pasientene får i denne modulen grundig opplæring i hva dietten 
består av, kilder til tungtfordøyelige karbohydrater og hvordan 
man kan sette sammen et balansert kosthold lavt på FODMAPs.  
Pasienten får opplæring i fordøyelsen, næringsstoffene,  











filmer.    
I denne modulen har pasienten mulighet til å kontakte en klinisk 
ernæringsfysiolog via HelseNorge.no. Spørsmål vil bli besvart 
mandag og fredag, og pasienten vil motta en SMS når svar 
foreligger på HelseNorge.no.  
  
2-6 uker  
  
Tekst, lister og oppskrifter med utskriftsvennlig versjoner, filmer 










Etter 2-6 uker med et lav FODMAP kosthold, til pasienten er 
symptomfri, skal pasienten teste toleransen for hver enkelt 
FODMAP-gruppe. Pasienten får steg-for-steg informasjon om 
hvordan reintroduksjonen skal gjennomføres, og får forslag til 
testmatvarer og mengder. Under reintroduksjon av matvarer 






Målet er at pasienten står igjen med et kosthold uten 
unødvendige restriksjoner og reduserte plager (reduksjon på 
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Appendix 2: Approval from Regional Committees for Medical and Health Research Ethics 
(REC) 
 
REK vest Øyvind Straume 55978497   05.09.2016 2016/1098/REK vest 
  Deres dato: Deres referanse: 
  14.06.2016 
  
Vår referanse må oppgis ved alle henvendelser 
 Birgitte Berentsen 
Medisinsk avdeling 
2016/1098  Mage-tarmskolen på internett og mobilapplikasjon  
Forskningsansvarlig: Helse Bergen HF, Helse Bergen Prosjektleder: Birgitte Berentsen 
Vi viser til søknad om forhåndsgodkjenning av ovennevnte forskningsprosjekt. Søknaden ble behandlet av Regional komité for medisinsk 
og helsefaglig forskningsetikk (REK vest) i møtet 18.08.2016. Vurderingen er gjort med hjemmel i helseforskningsloven (hfl.) § 10, jf. 
forskningsetikkloven § 4. 
Prosjektomtale 
Studien skal identifisere om veiledet selvhjelp over internett leder til endringer i abdominale symptomer og livskvalitet hos pasienter med 
irritabel tarmsyndrom. 60 pasienter skal igjennom et 7-9 ukers opplæring -og behandlingsopplegg (Mage-tarmskolen) hvor de veiledes 
igjennom 5 tverrfaglige moduler utviklet av spesialister innen gastroenterologi, manuellterapi/fysioterapi, psykiatri/psykosomatikk, og 
klinisk ernæringsfysiologi. Studiens mål er å påvise nytteeffekter i form av forbedret livskvalitet, reduksjon av abdominale symptomer, gi 
ny kunnskap om tverrfaglig pasienttilnærming, samt danne grunnlag for et fremtidig nasjonalt prosjekt. 
Vurdering 
Forsvarlighet 
Data skal innsamles via spørreskjema. Søknaden og datainnsamlingen fremstår som velbegrunnet, og komiteen har ingen innvendinger til 
søknad eller protokoll. 
Informasjonsskrivet 
Informasjonsskrivet må være noe tydeligere på hva selve Mage-tarmskolen handler om, og hvorfor deltakerne blir rekruttert til studien. 
Revidert informasjonsskriv må ettersendes til REK vest. 
Prosjektslutt og håndtering av data 
Prosjektslutt er satt til 01.08.2026 og koblingsnøkkel skal destrueres ved prosjektslutt. REK vest har ingen innvendinger til dette. Det 
fremgår av søknaden at data skal lagres i låst skap på prosjektleder sitt kontor. 
Komiteen setter som vilkår at lagring gjøres i tråd med forskningsansvarlig (Helse Bergen HF) sine rutiner. 
Vilkår 
Informasjonsskrivet skal revideres i tråd med ovennevnte merknad og ettersendes REK vest. 




Besøksadresse: Telefon: 55975000 All post og e-post som inngår i   Kindly address all mail and e-mails to 
Armauer Hansens Hus (AHH),           E-post: rek-vest@uib.no                     saksbehandlingen, bes adressert til REK    the Regional Ethics Committee, REK  
Tverrfløy Nord, 2 etasje. Rom            Web: http://helseforskning.etikkom.no/               vest og ikke til enkelte personer                 vest, not to individual staff 
281. Haukelandsveien 28 
Region: Saksbehandler: Telefon: 








REK vest godkjenner prosjektet på betingelse av at ovennevnte vilkår tas til følge. 
Sluttmelding og søknad om prosjektendring 
Prosjektleder skal sende sluttmelding til REK vest på eget skjema senest 01.02.2027, jf. hfl. § 
12. Prosjektleder skal sende søknad om prosjektendring til REK vest dersom det skal gjøres vesentlige endringer i forhold til de 
opplysninger som er gitt i søknaden, jf. hfl. § 11. 
Klageadgang 
Du kan klage på komiteens vedtak, jf. forvaltningsloven § 28 flg. Klagen sendes til REK vest. Klagefristen er tre uker fra du mottar dette 
brevet. Dersom vedtaket opprettholdes av REK vest, sendes klagen videre til Den nasjonale forskningsetiske komité for medisin og 
helsefag for endelig vurdering. 





























Appendix 3: REC approval of alterations in the project 
 
REK vest Øyvind Straume 55978497   13.10.2016 2016/1098/REK vest 
  Deres dato: Deres referanse: 
  10.10.2016 
 
Vår referanse må oppgis ved alle henvendelser 
 Birgitte Berentsen 
Medisinsk avdeling 
2016/1098 Mage-tarmskolen på internett og mobilapplikasjon 
Forskningsansvarlig: Helse Bergen HF Prosjektleder: Birgitte Berentsen  
Vi viser til søknad om prosjektendring datert 10.10.2016 for ovennevnte forskningsprosjekt. Søknaden er behandlet av leder for REK vest 
på fullmakt, med hjemmel i helseforskningsloven § 11. 
Vurdering 
Ønsket endring 
Prosjektendringen innebærer å inkludere en 15-åring i prosjektet. 
REK vest ved leder vurderte saken. 
Vurdering 
Deltakelse i studien kan være fordelaktig for 15-åringen.  Vi vurderer dette til å være en forsvarlig endring å gjennomføre, og har ingen 
innvendinger. 
Vedtak 
REK vest godkjenner prosjektendringen i samsvar med forelagt søknad.  
Klageadgang 
Du kan klage på komiteens vedtak, jf. forvaltningsloven § 28 flg. Klagen sendes til REK vest. Klagefristen er tre uker fra du mottar dette 
brevet. Dersom vedtaket opprettholdes av REK vest, sendes klagen videre til Den nasjonale forskningsetiske komité for medisin og 
helsefag for endelig vurdering. 




Øyvind Straume seniorkonsulent 
 Kopi til: postmottak@helse-bergen.no   
Besøksadresse: Telefon: 55975000 All post og e-post som inngår i  Kindly address all mail and e-mails to 
Armauer Hansens Hus (AHH),            E-post: rek-vest@uib.no                     saksbehandlingen, bes adressert til REK    the Regional Ethics Committee, REK  
Tverrfløy Nord, 2 etasje. Rom             Web: http://helseforskning.etikkom.no/              vest og ikke til enkelte personer                 vest, not to individual staff 





Region: Saksbehandler: Telefon: 





Appendix 4: REC approval of inclusion of patients in the control group 
 
 
REK vest Trine Anikken Larsen 55978496   07.12.2016 2016/1098/REK vest 
  Deres dato: Deres referanse: 
  21.11.2016 
  
Vår referanse må oppgis ved alle henvendelser 
 Birgitte Berentsen 
Medisinsk avdeling 
2016/1098 Mage-tarmskolen på internett og mobilapplikasjon 
Forskningsansvarlig: Helse Bergen HF Prosjektleder: 
Birgitte Berentsen  
Vi viser til søknad om prosjektendring datert 21.11.2016 for ovennevnte forskningsprosjekt. 
Søknaden er behandlet av leder for REK vest på fullmakt, med hjemmel i helseforskningsloven § 11. 
Vurdering 
Omsøkt endring 
Prosjektleder søker om å øke antall deltakere i studien.  
Vurdering 
Forskergruppen ønsker å sammenlikne spørreskjemabesvarelsen til pasienter som deltar i denne 
studien med pasienter som er henvist til Gastroseksjonen, Medisinsk avdeling, og innkalt til vanlig 
IBS-skole ved Læring og Mestringssenteret i Helse Bergen. De nye pasientene vil motta samme 
spørreskjema som i denne studien.  
REK vest har ingen innvendinger til at nevnte pasientgruppe inkluderes i studien, men setter som 
vilkår at det innhentes samtykke fra disse pasientene på tilsvarende måte som den opprinnelige 
pasientgruppen. REK vest ber om at det sendes inn i revidert informasjonsskriv tilpasset 
pasientgruppen som nå skal inkluderes.  
 
Vilkår 
 Det må innhentes aktivt samtykke fra den nye pasientgruppen som skal inkluderes i studien. 
Informasjonsskrivet sendes til REK vest.  
 
 
Besøksadresse: Telefon: 55975000 All post og e-post som inngår i Kindly address all mail and e-mails to 
Armauer Hansens Hus (AHH),       E-post: rek-vest@uib.no                     saksbehandlingen, bes adressert til REK  the Regional Ethics Committee, REK  
Tverrfløy Nord, 2 etasje. Rom        Web: http://helseforskning.etikkom.no/                vest og ikke til enkelte personer                vest, not to individual staff 
281. Haukelandsveien 28 
Region: Saksbehandler: Telefon: 







REK vest godkjenner prosjektendringen på betingelse av at ovennevnte vilkår tas til følge.   
Klageadgang 
Du kan klage på komiteens vedtak, jf. forvaltningsloven § 28 flg. Klagen sendes til REK vest. 
Klagefristen er tre uker fra du mottar dette brevet. Dersom vedtaket opprettholdes av REK vest, 
sendes klagen videre til Den nasjonale forskningsetiske komité for medisin og helsefag for endelig 
vurdering. 
 
Med vennlig hilsen 
Marit Grønning Prof. 
Dr.med. komitéleder 
Trine Anikken Larsen 
seniorkonsulent 



























Forespørsel om deltakelse i forskningsprosjektet:                                 
«Mage-tarmskolen» 
 
Bakgrunn og hensikt                                                                                                           
Dette er et spørsmål til deg om å delta i en forskningsstudie ved Haukeland 
Universitetssykehus. Formålet med studien er å identifisere om veiledet selvhjelp over 
internett leder til endringer i mageplager og livskvalitet hos personer med irritabel tarm. 
Forskningsstudien skal også kvalitetssikre Mage-tarmskolen som helsetiltak.  
Hva innebærer studien?                                                                                                         
Som deltager skal du gå igjennom et opplæring -og behandlingsprogram via internett. Du 
veiledes igjennom 5 tverrfaglige moduler utviklet av spesialister innen gastroenterologi, 
manuellterapi/fysioterapi, psykiatri/psykosomatikk, og klinisk ernæringsfysiologi. Innholdet 
er en sammensetting av tekst, film, videosnutter og bilder. Det vil ta deg 7-9 uker og jobbe 
igjennom programmet. Det høres kanskje litt lenge ut, men flere uker er nødvendig når vi 
veileder deg igjennom den siste delen av programmet; kostholdsveiledning i modul 5.  
Hele den elektroniske plattformen er utviklet av Helse Bergen’s Seksjon for eHelse. Når du 
logger deg på bruker du høyeste sikkerhetsnivå 4, for eksempel bankbrikken din (BANK-ID). 
Studien innebærer en statistisk analyse av medisinske spørreskjemaene som du får elektronisk 
tilgang til. Ved å signere på dette samtykkeskjemaet samtykker du også til at vi kan ta kontakt 
med deg 3 måneder etter din deltagelse ved Mage-tarmskolen. Om 3 og 6 måneder vil vi ta 
kontakt med deg og be deg fylle ut de samme skjemaene en gang til.  
Mulige fordeler og ulemper                                                                                                  
Ved å delta i studien gir du Helse Bergen muligheten til å evaluere Mage-tarmskolen som 
tverrfaglig helsetiltak, samt hjelpe oss til å forbedre helsetiltaket. Studien involverer ingen 
ekstra undersøkelser som innebærer ubehag eller risiko.  
Hva skjer med informasjonen om deg?                                                                                
Det er frivillig å delta i studien. Om du nå sier ja til å delta, kan du senere når som helst og 
uten å oppgi noen grunn, trekke tilbake ditt samtykke. Informasjonen som registreres om deg 
skal kun brukes slik som beskrevet i hensikten med studien.                                                  
Alle opplysningene om deg vil bli behandlet uten navn og fødselsnummer eller andre direkte 
gjenkjennende opplysninger. Et tilfeldig nummer blir tildelt opplysningene som lagres om 
deg. Det er bare prosjektleder i studien som vil ha tilgang til nøkkelen som kobler dine 
spørreskjemabesvarelser til deg, og dette vil lagres separat fra dataene vi samler inn. Når 
studien er over vil din personlige informasjon destrueres, og dataene vil lagres anonymt. Det 
vil da ikke være mulig å koble din identitet til dine besvarelser.  






Ytterligere informasjon om studien finnes i kapittel A, og dine rettigheter finnes i 
Kapittel B. Ved ytterligere spørsmål, kontakt Birgitte Berentsen, Nasjonal 
Kompetansetjeneste for Funksjonelle Mage-tarmsykdommer, tlf 55 97 29 99 eller epost 
birgitte.berentsen1@helse-bergen.no. 
Kapittel A: Utdypende forklaring om hva studien innebærer 
Kriteriet for deltagelse i forskningsstudien, «Mage-tarmskolen», er at du har fått diagnosen 
«irritabel tarm» hos fastlegen eller på sykehuset hos spesialisthelsetjenesten. Det er viktig at 
du ikke opplever det som vi kaller for «rød-flagg symptomer» som blod i avføringen, feber, 
uforklarlig raskt vekttap eller diare om natten mens du sover.  
Denne forskningsstudien skal identifisere om veiledet selvhjelp over internett leder til 
endringer i mageplager og livskvalitet hos personer med irritabel tarm.                                  
Du vil bli bedt om å fylle medisinske spørreskjema før du begynner på «Mage-tarmskolen». 
Skjemaene er listet opp nedenfor. Vi vil kontakte deg igjen 3 og 6 måneder etter deltagelsen, 
og be deg fylle ut de samme skjemaene en gang til. Det tar ca. 30 minutter å fylle ut 
skjemaene, per gang. Vi vil analysere besvarelsene du har gitt i skjemaene og gjøre en 
statistisk analyse for å se om dine mageplager og livskvalitet har endret seg etter deltagelsen i 
«Mage-tarmskolen».  Det vil ikke være mulig å identifisere deg eller dine besvarelser i 
materialet som publiseres etter studien.                                                                                  
Studien vil ikke medføre noen økonomiske utgifter for deg som deltager.  
Kapittel B: Informasjon om dine rettigheter 
Personvern                                                                                                                           
Opplysninger som registreres om deg er besvarelser på følgende skjema: 
1) Gradering av mageplager (IBS-SSS)                                                                                      
2) Spørreskjema om mageplager (ROMA III)                                                                                    
3) Spørsmål om uro og bekymring (EPQ-N-12)                                                                         
4) Spørsmål som handler om hvordan du oppfatter helsen din (RAND-36)                                         
5) Personlighetstest (NEO-PI-3 og NEO-FFI-3)                                                                         
6) Spørsmål om angst og depresjon (HAD)                                                                                        
7) Spørsmål om livskvalitet i forbindelse med mageplager (IBS-QOL)                                                
8) NKFMs spørreskjema om symptomer, hyppighet og sykehusbesøk. 
Informasjonen du gir oss vil registreres og lagres i en elektronisk database på en 
forskningsserver ved Haukeland Universitetssykehus. Denne databasen vil ikke inneholde 
identifiserbar informasjon om deg. Ditt navn og besvarelsene som tilhører deg vil kodes med 
et tilfeldig nummer. Nøkkelen til koden er det bare prosjektleder som har tilgang til.  
Helse Bergen HF, Haukeland Universitetssykehus ved administrerende direktør er 
forskningsansvarlig. 
 
Informasjon om utfallet av studien                                                                                  
Årsrapporter som presenterer resultater fra foretakets forskningsprosjekter er offentlig 
tilgjengelige på http://helse-bergen.no/NKFM og/eller http://forskningsprosjekter.ihelse.net/. 







Skjema for samtykke til deltakelse i forskningsprosjekt - Voksne 
over 16 år   
  
Prosjekttittel  




Prosjektleders navn  
Birgitte Berentsen  
  
Klinikk/avdeling  
Nasjonal Kompetansetjeneste for 
Funksjonelle Magetarmsykdommer, 
Medisinsk Avd., HUS  
Det er frivillig å delta i studien. Dersom du ønsker å delta, undertegner du denne 
samtykkeerklæringen. Om du nå sier ja til å delta, kan du senere når som helst og uten å oppgi 
noen grunn, trekke tilbake ditt samtykke uten at det påvirker din øvrige behandling. Dersom 
du senere ønsker å trekke deg eller har spørsmål til studien, kan du kontakte prosjektleder.   
  
  
Jeg er villig til å delta i forskningsprosjektet:  
  












Fylles ut av representant for forskningsprosjektet  
  






Underskrift  Brukerkode (4-
tegnskode)  
  


























Her kommer nødvendig informasjon for å kunne være med vårt forskningsprosjekt, samt litt 
informasjon om Mage-tarmskolen.  
Mage-tarmskolen er en internettbasert skole som består av 5 moduler. I modul 1 vil du bli 
introdusert for lege Trygve Hausken, hvor du blant annet får kunnskap om hvordan 
fordøyelsessystemet fungerer og hva irritabel tarm er. I Modul 2 vil du bli introdusert for 
fysioterapeut Eirik Østvold, hvor du vil lære om sammenhengen mellom irritabel tarm og anspenthet 
og muskelplager, samt få demonstrasjon i riktig pusteteknikk. I modul 3 vil du bli introdusert for 
klinisk ernæringsfysiolog Synne Ystad, hvor du vil lære om generelle kost- og livsstilsråd. I modul 4 vil 
psykiater Jørn Bødtker introdusere kognitiv terapi, samt gi deg hjemme-øvelser i 
oppmerksomhetstrening og eksponering. I modul 5 vil klinisk ernæringsfysiolog Synne Ystad og klinisk 
ernæringsfysiolog Ingrid Sørgard Skjold gi opplæring i lavFODMAP-dietten, samt gi tilgang på 
matlagingsfilmer. I denne siste modulen, vil du også få muligheten til å stille spørsmål til en klinisk 
ernæringsfysiolog dersom det er noe du lurer på. 



















Vedlagt har vi sendt samtykkeskjema og 2 spørreskjema som du må skrive under på og sende 
tilbake til oss, helst så fort som mulig, for å kunne delta i studien. 
Dersom vi har fått samtykkeskjema og spørreskjema underskrevet fra deg vil du bli registrert som 
deltaker i vårt forskningsprosjekt. Du vil dermed bli tilsendt en tekstmelding med en link hvor du kan 
logge deg på. Du kan selv disponere når du har tid til å gjennomføre skolen. Vi anbefaler å reflektere 
og sette av tid til å utføre hjemme-oppgavene slik at du får størst mulig utbytte av Mage-tarmskolen.  
Vi håper du setter av tid til å svare på spørreskjemaene du får på starten av Mage-tarmskolen, samt 
ettersendt etter fullføring av skolen, slik at vi kan kvalitetssikre og dermed videreutvikle en nasjonal 
Mage-tarmskole som kan hjelpe enda flere personer med irritabel tarm. 
Vi har tro på at økt forståelse og kunnskap vil gi økt trygghet og mulighet for bedre mestring av 
kronisk/tilbakevendende plager. Vi håper derfor at denne hjelp til selvhjelp vil bidra til at du får et 










Med vennlig hilsen 
Nasjonal kompetansetjeneste for Funksjonelle Mage-tarmsykdommer, 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































-Intro med Birgitte https://youtu.be/aJ6Lrjo328c  
-Intro med Silje https://youtu.be/wlga--7j2Kc  
 
MODUL1 (LEGE) 
-Intro med Trygve https://youtu.be/3Jk-3C8cSYw  
-Fordøyelsessystemet https://youtu.be/1LHF3CpucQw  
-Magesekk med suppe https://www.youtube.com/watch?v=EP0D9uCv-9I  
- Fordøyelse og absorpsjon av næringsstoffer https://youtu.be/jBE2ZGBqfU0  
 
MODUL2 (FYSIO) 
-Intro med Eirik https://youtu.be/P5ASDxkTMBo  
-Eirik med modell viser feil pustemønster https://youtu.be/BoMhEOTpyl4  
-Eirik med modell viser god kroppsholdning https://youtu.be/prbPUQaKBwI  
 
MODUL3 (GENERELLE RÅD MED KEF) 
-Intro med Synne https://youtu.be/vofPUVztBas  
 
MODUL4 (PSYKIATER) 
-Intro med Jørn https://youtu.be/WmrTmBeJwSA  
 
MODUL 5 (FODMAP MED KEF) 
-Intro med Synne https://youtu.be/bkf0s46nXxc  
- Fordøyelse og absorpsjon av næringsstoffer https://youtu.be/jBE2ZGBqfU0  
-Intro –hva er FODMAP https://youtu.be/bCSYrL_AQzo 
-Hvordan FODMAP virker i tarmen og hvilke symptomer de gir  https://youtu.be/iYO0VwWzsJE 
-FODMAP-gruppene og matvarer https://youtu.be/7yjoAtaVgiA 
-Frokost og lunsj-alternativer https://youtu.be/VU5ruaFBjJ0  
-Middag https://youtu.be/MbwT5BvRANk 
-Smakstilsetninger https://youtu.be/LIKx3gCGznc  
-Kostfiber og tilsetninger https://youtu.be/uF7kwIY46aY  
-Avslutning med Silje https://youtu.be/PnzEmVpjjYM  
